Black Swan Sale

50% Off Elite

Get our most powerful screeners, new charting tools, and the fastest ad-
free experience at our best price ever. This deal may never happen again.

Open in Screener

NUVL

Nuvalent Inc

Nov 25 • 04:00PM ET

109.86

+0.33 0.30 %

Healthcare • Biotechnology • USA • NASD

Peers: ARQT ABUS TIL ALLO BEAM IMTX KRYS RGNX DTIL

| Held by: VTI IWM VB XBI VBR VXF IWO IBB SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-5.32	Insider Own	35.45%	Shs Outstand	66.84M	Perf Week	5.39%
Market Cap	7.99B	Forward P/E	-	EPS next Y	-5.79	Insider Trans	-4.60%	Shs Float	46.93M	Perf Month	12.43%
Enterprise Value	7.04B	PEG	-	EPS next Q	-1.48	Inst Own	76.25%	Short Float	9.94%	Perf Quarter	44.31%
Income	-381.44M	P/S	-	EPS this Y	-45.50%	Inst Trans	1.25%	Short Ratio	8.45	Perf Half Y	53.80%
Sales	0.00M	P/B	9.39	EPS next Y	-1.19%	ROA	-35.18%	Short Interest	4.66M	Perf YTD	40.34%
Book/sh	11.70	P/C	8.47	EPS next 5Y	-3.38%	ROE	-38.79%	52W High	112.88 -2.68%	Perf Year	18.47%
Cash/sh	12.97	P/FCF	-	EPS past 3/5Y	-59.96% -74.22%	ROIC	-45.12%	52W Low	55.53 97.82%	Perf 3Y	256.11%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.87% 5.88%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-52.84%	Oper. Margin	-	ATR (14)	5.54	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	10.73	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	65.35	Recom	1.17
Dividend Gr. 3/5Y	- -	Current Ratio	10.73	EPS Q/Q	-32.15%	SMA20	10.09%	Beta	1.29	Target Price	141.82
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	19.49%	Rel Volume	1.50	Prev Close	109.53
Employees	142	LT Debt/Eq	0.00	Earnings	Oct 30 BMO	SMA200	37.64%	Avg Volume	551.73K	Price	109.86
IPO	Jul 29, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-8.32% -	Trades		Volume	828,898	Change	0.30%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-24-25	Initiated	Truist	Buy
Nov-12-25	Initiated	Canaccord Genuity	Buy	$126
Oct-16-25	Resumed	Stifel	Buy	$115
Oct-15-25	Initiated	Cantor Fitzgerald	Overweight	$135
Sep-04-25	Resumed	Guggenheim	Buy	$122
Sep-03-25	Initiated	Raymond James	Outperform	$105
Aug-19-25	Initiated	Piper Sandler	Overweight	$112
Mar-14-25	Upgrade	UBS	Neutral → Buy	$100
Dec-30-24	Initiated	H.C. Wainwright	Buy	$110
Oct-24-24	Initiated	UBS	Neutral	$100
Aug-29-24	Initiated	Barclays	Overweight	$100
Apr-17-24	Initiated	Jefferies	Buy	$97
Apr-01-24	Upgrade	Leerink Partners	Market Perform → Outperform	$69 → $110
Feb-28-24	Resumed	Guggenheim	Buy	$99
Feb-23-24	Initiated	Robert W. Baird	Outperform	$105
Sep-27-23	Initiated	Stifel	Buy	$65
Aug-08-23	Initiated	SVB Securities	Market Perform	$42
Jul-24-23	Initiated	Guggenheim	Buy	$56
Jan-18-23	Initiated	Wedbush	Outperform	$39
Jun-24-22	Initiated	BMO Capital Markets	Outperform	$28

Show Previous Ratings

Nov-24-25 04:01PM	Nuvalent Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares from Selling Stockholders (PR Newswire)
Nov-19-25 04:19PM	Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC (PR Newswire)
Nov-18-25 11:50PM	Nuvalent Announces Pricing of Public Offering of Common Stock (PR Newswire)
06:24AM	Nuvalent aiming for approval on pivotal trial data for NSCLC candidate (Clinical Trials Arena)
Nov-17-25 04:40PM	Nuvalent Tops A Profit-Taking Zone On Its 'Unprecedented' Test Results In Lung Cancer (Investor's Business Daily) +11.92%
04:01PM	Loading…
04:01PM	Nuvalent Announces Public Offering of Common Stock (PR Newswire)
06:32AM	Nuvalent Unveils A New Promise For Hard-To-Treat Lung Cancer (Investor's Business Daily)
06:30AM	Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC (PR Newswire)
Nov-14-25 04:01PM	Nuvalent Announces Timing of Topline Pivotal Data for TKI Pre-treated Patients with Advanced ALK-positive NSCLC from ALKOVE-1 Clinical Trial of Neladalkib (PR Newswire)
Nov-12-25 09:45AM	Carvana initiated, AT upgraded: Wall Street's top analyst calls (The Fly)
Nov-04-25 05:12PM	Nuvalent to Present Patient-Reported Outcomes Data from ARROS-1 Trial of ROS1-Selective Inhibitor, Zidesamtinib, at 2025 IASLC ASCO North America Conference on Lung Cancer (PR Newswire)
Oct-30-25 06:30AM	Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2025 Financial Results (PR Newswire)
Oct-18-25 06:00AM	Nuvalent Presents Preliminary Data for Neladalkib in Advanced ALK-positive Solid Tumors Beyond NSCLC at ESMO 2025 (PR Newswire)
Oct-13-25 12:53PM	Nuvalent to Present New Preclinical Data for HER2-Selective Inhibitor, NVL-330, at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (PR Newswire)
Sep-24-25 06:30AM	Nuvalent to Participate in the UBS 2025 Virtual Oncology Day (PR Newswire)
04:45AM	Loading…
Sep-07-25 04:45AM	Nuvalent Presents Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025 (PR Newswire)
Sep-02-25 01:34AM	Piper Sandler Initiates Nuvalent (NUVL) Amid Key Cancer Drug Catalysts (Insider Monkey)
Aug-28-25 06:30AM	Nuvalent to Participate in the Cantor Global Healthcare Conference 2025 (PR Newswire)
Aug-13-25 01:06PM	Nuvalent to Present Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025 Presidential Symposium (PR Newswire)
Aug-07-25 06:30AM	Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results (PR Newswire) -6.56%
Jul-21-25 06:30AM	Nuvalent Announces Initiation of ALKAZAR Phase 3 Randomized, Controlled Trial Evaluating Neladalkib for Patients with TKI-naïve ALK-positive NSCLC (PR Newswire)
06:30AM	Nuvalent Announces Initiation of ALKAZAR Phase 3 Randomized, Controlled Trial Evaluating Neladalkib for Patients with TKI-naive ALK-positive NSCLC (PR Newswire)
Jul-06-25 04:00AM	Nuvalent Announces Positive Pivotal Data for Zidesamtinib in Lung Cancer (Insider Monkey)
Jun-25-25 10:20AM	Nuvalent price target raised to $140 from $125 at Leerink (TipRanks)
10:15AM	Nuvalent price target raised to $130 from $110 at H.C. Wainwright (TipRanks)
Jun-24-25 06:30AM	Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC (PR Newswire)
06:30AM	Chasing rivals, Nuvalent to seek approval of targeted lung cancer drug (BioPharma Dive)
Jun-23-25 04:30PM	Nuvalent Announces Timing of Pivotal Data for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC from ARROS-1 Clinical Trial of Zidesamtinib (PR Newswire)
Jun-18-25 04:30PM	Nuvalent Appoints Christy Oliger to Board of Directors (PR Newswire)
May-08-25 07:31AM	Nuvalent Outlines Recent Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2025 Financial Results (PR Newswire) +7.31%
01:09PM	Loading…
Apr-29-25 01:09PM	Nuvalent Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor (PR Newswire)
Apr-23-25 08:48PM	Nuvalent, Inc. (NUVL): Among Takeover Rumors Hedge Funds Are Buying (Insider Monkey)
12:47PM	Is Nuvalent, Inc. (NUVL) Among the Best Guru Stocks to Buy According to Wall Street Analysts? (Insider Monkey)
10:28AM	Nuvalent to Present Trial in Progress Posters for the ALKAZAR Trial of Neladalkib and HEROEX-1 Trial of NVL-330 at the 2025 American Society of Clinical Oncology Annual Meeting (PR Newswire)
Apr-08-25 04:00PM	Nuvalent: Cannot Make Sense Of The Valuation (Seeking Alpha) -8.29% +9.07%
Apr-01-25 08:25AM	Is Nuvalent (NUVL) the Best Debt Free Mid Cap Stock to Buy Now? (Insider Monkey)
06:30AM	Nuvalent to Participate in the Stifel 2025 Virtual Targeted Oncology Forum (PR Newswire)
Mar-25-25 05:24PM	Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor, Neladalkib, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2025 (PR Newswire)
Mar-20-25 09:05AM	Invesco Health Care Fund Q4 2024 Commentary (SeekingAlpha)
Feb-28-25 06:30AM	Nuvalent to Participate in Upcoming March Investor Conferences (PR Newswire)
Feb-27-25 06:30AM	Nuvalent Outlines Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
Feb-11-25 01:47PM	Why Insiders Are Selling Nuvalent, Inc. (NUVL) Recently (Insider Monkey)
Jan-20-25 03:07PM	Is Nuvalent, Inc. (NUVL) Among Billionaire Joseph Edelmans Long-Term Stock Picks? (Insider Monkey)
Jan-13-25 06:30AM	Nuvalent Details Strategy to Seek First Potential Approval in 2026 and Outlines Key Anticipated 2025 Milestones (PR Newswire) -6.20%
Dec-30-24 09:43AM	American Air upgraded, Nordstrom downgraded: Wall Street's top analyst calls (The Fly)
Dec-19-24 06:30AM	Nuvalent to Present at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-09-24 06:30AM	Nuvalent Appoints Grant Bogle to Board of Directors (PR Newswire)
Nov-26-24 06:52AM	Nuvalent to Participate in the Piper Sandler 36th Annual Healthcare Conference (PR Newswire)
Nov-12-24 06:30AM	Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results (PR Newswire)
Sep-18-24 04:05PM	Nuvalent Announces Closing of Upsized Public Offering of Common Stock (PR Newswire)
Sep-16-24 10:23PM	Nuvalent Announces Pricing of Upsized Public Offering of Common Stock (PR Newswire) +28.27% -6.61%
04:04PM	Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths (Investor's Business Daily)
11:18AM	Cancer Biotech Nuvalents Stock Jumps on Positive Data (Barrons.com)
07:00AM	Nuvalent Announces Public Offering of Common Stock (PR Newswire)
Sep-14-24 07:57PM	Nuvalent, Inc. (NUVL): Among Hedge Funds Top Biotech Stock Picks (Insider Monkey)
05:29PM	Nuvalent, Inc. (NUVL): Short Seller Sentiment is Bearish on This Cancer Stock (Insider Monkey)
05:00AM	Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines (PR Newswire)
Sep-13-24 09:53AM	Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655 (PR Newswire) +7.06%
Sep-09-24 06:30AM	Updated Data for Nuvalent's ALK-Selective Inhibitor, NVL-655, and ROS1-Selective Inhibitor, Zidesamtinib, Continue to Support Potential Best-in-Class Profiles (PR Newswire)
Aug-29-24 06:30AM	Nuvalent to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (PR Newswire)
Aug-08-24 06:30AM	Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2024 Financial Results (PR Newswire)
Jul-23-24 04:52AM	Nuvalent doses first subject in Phase Ia/Ib trial of lung cancer treatment (Clinical Trials Arena)
Jul-22-24 06:30AM	Nuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective Inhibitor (PR Newswire)
Jul-16-24 06:30AM	Nuvalent to Present Updated Data for ROS1-Selective Inhibitor, Zidesamtinib, and ALK-Selective Inhibitor, NVL-655, at the ESMO Congress 2024 (PR Newswire)
Jul-11-24 06:30AM	Nuvalent Announces Promotion of Henry Pelish, Ph.D. to Chief Scientific Officer (PR Newswire)
Jun-24-24 06:00AM	3 Short-Squeeze Stocks Poised for a Jaw-Dropping Rally (InvestorPlace)
May-29-24 06:30AM	Nuvalent to Participate in the 2024 Jefferies Global Healthcare Conference (PR Newswire)
May-17-24 04:48PM	Nuvalent Insider Sold Shares Worth $345,450, According to a Recent SEC Filing (MT Newswires)
06:31AM	FDA grants breakthrough therapy status for Nuvalents NVL-655 (Pharmaceutical Technology)
May-16-24 04:23PM	Nuvalent Gets Breakthrough Therapy Designation for Lung Cancer Treatment Candidate (MT Newswires)
04:01PM	Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655 (PR Newswire)
May-09-24 01:56PM	NUVL Stock Earnings: Nuvalent Misses EPS for Q1 2024 (InvestorPlace)
09:27AM	Nuvalent Q1 Loss Widens (RTT News)
07:19AM	Nuvalent Q1 Net Loss Widens (MT Newswires)
06:30AM	Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results (PR Newswire)
May-08-24 05:22PM	Nuvalent Insider Sold Shares Worth $2,605,525, According to a Recent SEC Filing (MT Newswires)
10:21AM	Why Earnings Season Could Be Great for Nuvalent (NUVL) (Zacks)
May-01-24 05:05PM	Nuvalent Insider Sold Shares Worth $2,666,555, According to a Recent SEC Filing (MT Newswires)
Apr-08-24 04:30PM	Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 (PR Newswire)
Apr-05-24 07:00PM	Chief Legal Officer Deborah Miller Sells 3,000 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
06:30PM	ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors (Barrons.com)
Mar-29-24 07:01PM	Chief Legal Officer Deborah Miller Sells 22,000 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
Mar-25-24 07:01PM	Chief Development Officer Darlene Noci Sells 20,000 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
Mar-19-24 07:01PM	Director Emily Conley Sells 13,333 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
Mar-05-24 04:52PM	Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024 (PR Newswire)
Feb-29-24 04:32AM	Nuvalent Inc (NUVL) Reports Full Year and Q4 2023 Financial Results with Strong Cash Position ... (GuruFocus.com)
Feb-27-24 06:30AM	Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results (PR Newswire)
06:15AM	Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520 (PR Newswire)
Feb-22-24 04:00AM	13 Best Short Squeeze Stocks To Buy Now (Insider Monkey)
Feb-12-24 06:30AM	Nuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical Trial for Patients with ALK-Positive NSCLC and other Solid Tumors (PR Newswire)
Feb-01-24 06:30AM	Nuvalent to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (PR Newswire)
Jan-08-24 06:30AM	Nuvalent Announces 'OnTarget 2026' Operating Plan and Key Anticipated Milestones (PR Newswire)
Dec-22-23 03:01PM	Director Anna Protopapas Sells 5,000 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
Dec-21-23 01:01PM	Chief Development Officer Darlene Noci Sells 40,000 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
06:30AM	Nuvalent to Present at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Nov-14-23 07:15PM	Nuvalent Inc (NUVL) Reports Q3 2023 Financial Results and Pipeline Progress (GuruFocus.com)
06:30AM	Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter 2023 Financial Results (PR Newswire)
Nov-04-23 07:02AM	Insider Sell: Darlene Noci Sells 3,000 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
Nov-01-23 06:30AM	Nuvalent to Participate in the BMO Virtual BioPharma Spotlight Series: Oncology Day (PR Newswire)
Oct-23-23 02:50AM	7 Biotech Stocks to Get In Now Before Investors Catch On (InvestorPlace)

Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. Its pipeline includes ROS1 NSCLC, ALK NSCLC and HER2 NSCLC. The company was founded by Matthew D. Shair in January 2017 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Flynn James E	Director by Deputization	Nov 24 '25	Sale	95.44	742,574	70,874,975	8,299,225	Nov 24 08:00 PM
Balcom Alexandra	Chief Financial Officer	Nov 17 '25	Option Exercise	49.85	20,000	996,962	81,734	Nov 19 05:14 PM
Balcom Alexandra	Chief Financial Officer	Nov 18 '25	Option Exercise	72.35	729	52,743	62,463	Nov 19 05:14 PM
Balcom Alexandra	Chief Financial Officer	Nov 17 '25	Sale	99.45	20,000	1,989,025	61,734	Nov 19 05:14 PM
Balcom Alexandra	Chief Financial Officer	Nov 18 '25	Sale	104.26	729	76,005	61,734	Nov 19 05:14 PM
Miller Deborah Ann	Chief Legal Officer	Nov 17 '25	Option Exercise	6.89	24,200	166,738	73,286	Nov 19 05:13 PM
Miller Deborah Ann	Chief Legal Officer	Nov 17 '25	Sale	105.50	24,200	2,552,999	49,086	Nov 19 05:13 PM
DEBORAH MILLER	Officer	Nov 17 '25	Proposed Sale	96.50	17,200	1,659,800		Nov 17 04:37 PM
Alexandra Balcom	Officer	Nov 17 '25	Proposed Sale	93.72	13,854	1,298,397		Nov 17 04:09 PM
Noci Darlene	Chief Development Officer	Oct 30 '25	Option Exercise	27.85	4,000	111,400	52,034	Oct 31 04:31 PM
Noci Darlene	Chief Development Officer	Oct 30 '25	Sale	102.92	4,000	411,661	48,034	Oct 31 04:31 PM
Miller Deborah Ann	Chief Legal Officer	Oct 30 '25	Option Exercise	6.89	21,800	150,202	70,886	Oct 31 04:30 PM
Miller Deborah Ann	Chief Legal Officer	Oct 30 '25	Sale	103.16	21,800	2,248,943	49,086	Oct 31 04:30 PM
DEBORAH MILLER	Officer	Oct 30 '25	Proposed Sale	102.97	22,800	2,347,716		Oct 30 04:16 PM
Shair Matthew	Director	Oct 28 '25	Sale	100.27	32,455	3,254,263	1,383,044	Oct 29 04:31 PM
Shair Matthew	Director	Oct 27 '25	Sale	100.23	14,345	1,437,799	1,415,499	Oct 29 04:31 PM
Shair Matthew	Director	Oct 28 '25	Sale	100.27	9,154	917,872	203,322	Oct 29 04:31 PM
Shair Matthew	Director	Oct 27 '25	Sale	100.23	4,046	405,531	212,476	Oct 29 04:31 PM
Matthew Shair	Director	Oct 27 '25	Proposed Sale	100.00	64,350	6,435,000		Oct 27 04:09 PM
Matthew Shair	Director	Oct 27 '25	Proposed Sale	100.00	18,150	1,815,000		Oct 27 04:06 PM
Miller Deborah Ann	Chief Legal Officer	Oct 20 '25	Option Exercise	6.89	5,000	34,450	54,086	Oct 22 04:32 PM
Miller Deborah Ann	Chief Legal Officer	Oct 20 '25	Sale	94.91	5,000	474,550	49,086	Oct 22 04:32 PM
Porter James Richard	President and CEO	Oct 16 '25	Option Exercise	18.93	27,000	511,110	276,062	Oct 17 04:32 PM
Porter James Richard	President and CEO	Oct 16 '25	Sale	90.63	27,000	2,447,021	249,062	Oct 17 04:32 PM
Miller Deborah Ann	Chief Legal Officer	Oct 15 '25	Option Exercise	6.89	15,624	107,649	64,710	Oct 17 04:32 PM
Miller Deborah Ann	Chief Legal Officer	Oct 16 '25	Option Exercise	6.89	12,376	85,271	61,462	Oct 17 04:32 PM
Miller Deborah Ann	Chief Legal Officer	Oct 15 '25	Sale	89.98	15,624	1,405,848	49,086	Oct 17 04:32 PM
Miller Deborah Ann	Chief Legal Officer	Oct 16 '25	Sale	91.66	12,376	1,134,442	49,086	Oct 17 04:32 PM
Pelish Henry E.	Chief Scientific Officer	Oct 15 '25	Option Exercise	35.08	14,205	498,260	80,168	Oct 17 04:31 PM
Pelish Henry E.	Chief Scientific Officer	Oct 15 '25	Sale	90.04	14,205	1,279,018	65,963	Oct 17 04:31 PM
Balcom Alexandra	Chief Financial Officer	Oct 15 '25	Option Exercise	18.93	1,683	31,859	63,417	Oct 17 04:31 PM
Balcom Alexandra	Chief Financial Officer	Oct 15 '25	Sale	85.57	1,683	144,014	61,734	Oct 17 04:31 PM
James Richard Porter	Officer	Oct 16 '25	Proposed Sale	90.01	27,000	2,430,270		Oct 16 04:02 PM
DEBORAH MILLER	Officer	Oct 15 '25	Proposed Sale	84.66	54,000	4,571,640		Oct 15 04:37 PM
Balcom Alexandra	Chief Financial Officer	Oct 14 '25	Option Exercise	18.93	20,000	378,600	81,734	Oct 15 04:30 PM
Balcom Alexandra	Chief Financial Officer	Oct 13 '25	Option Exercise	14.79	20,000	295,825	81,734	Oct 15 04:30 PM
Balcom Alexandra	Chief Financial Officer	Oct 13 '25	Sale	88.51	20,000	1,770,288	61,734	Oct 15 04:30 PM
Balcom Alexandra	Chief Financial Officer	Oct 14 '25	Sale	86.20	20,000	1,724,016	61,734	Oct 15 04:30 PM
Pelish Henry E.	Chief Scientific Officer	Oct 13 '25	Option Exercise	36.39	7,637	277,903	73,600	Oct 15 04:30 PM
Pelish Henry E.	Chief Scientific Officer	Oct 14 '25	Option Exercise	25.67	2,433	62,460	68,396	Oct 15 04:30 PM
Pelish Henry E.	Chief Scientific Officer	Oct 13 '25	Sale	89.81	7,637	685,879	65,963	Oct 15 04:30 PM
Pelish Henry E.	Chief Scientific Officer	Oct 14 '25	Sale	85.78	2,433	208,699	65,963	Oct 15 04:30 PM
Alexandra Balcom	Officer	Oct 13 '25	Proposed Sale	89.32	48,558	4,337,206		Oct 14 04:08 PM
HENRY E PELISH	Officer	Oct 13 '25	Proposed Sale	88.10	21,842	1,924,280		Oct 14 07:43 AM
Balcom Alexandra	Chief Financial Officer	Oct 01 '25	Option Exercise	8.82	20,000	176,485	81,734	Oct 03 04:28 PM
Balcom Alexandra	Chief Financial Officer	Oct 01 '25	Sale	85.48	20,000	1,709,512	61,734	Oct 03 04:28 PM
Balcom Alexandra	Chief Financial Officer	Sep 30 '25	Option Exercise	6.89	20,000	137,800	81,734	Oct 01 08:17 PM
Balcom Alexandra	Chief Financial Officer	Sep 29 '25	Option Exercise	6.89	7,588	52,281	69,322	Oct 01 08:17 PM
Balcom Alexandra	Chief Financial Officer	Sep 30 '25	Sale	85.06	20,000	1,701,200	61,734	Oct 01 08:17 PM
Balcom Alexandra	Chief Financial Officer	Sep 29 '25	Sale	85.01	7,588	645,056	61,734	Oct 01 08:17 PM
Noci Darlene	Chief Development Officer	Sep 29 '25	Option Exercise	27.85	4,000	111,400	52,034	Oct 01 08:14 PM
Noci Darlene	Chief Development Officer	Sep 29 '25	Sale	83.07	4,000	332,288	48,034	Oct 01 08:14 PM
Darlene Noci	Officer	Sep 29 '25	Proposed Sale	81.30	12,000	975,600		Sep 29 04:08 PM
Alexandra Balcom	Officer	Sep 29 '25	Proposed Sale	81.30	60,000	4,878,000		Sep 29 04:07 PM
Porter James Richard	President and CEO	Sep 15 '25	Option Exercise	18.93	27,000	511,110	276,062	Sep 17 04:31 PM
Porter James Richard	President and CEO	Sep 15 '25	Sale	79.08	27,000	2,135,055	249,062	Sep 17 04:31 PM
Pelish Henry E.	Chief Scientific Officer	Sep 10 '25	Option Exercise	26.94	3,725	100,354	69,688	Sep 12 04:30 PM
Pelish Henry E.	Chief Scientific Officer	Sep 10 '25	Sale	78.83	3,725	293,642	65,963	Sep 12 04:30 PM
HENRY E PELISH	Officer	Sep 10 '25	Proposed Sale	78.73	6,158	484,819		Sep 10 04:38 PM
Pelish Henry E.	Chief Scientific Officer	Aug 29 '25	Option Exercise	1.00	5,007	4,986	65,963	Sep 03 04:30 PM
Noci Darlene	Chief Development Officer	Aug 25 '25	Option Exercise	27.85	4,000	111,400	52,034	Aug 27 04:30 PM
Noci Darlene	Chief Development Officer	Aug 25 '25	Sale	74.62	4,000	298,489	48,034	Aug 27 04:30 PM
Porter James Richard	President and CEO	Aug 15 '25	Option Exercise	18.93	27,000	511,110	276,062	Aug 19 04:30 PM
Porter James Richard	President and CEO	Aug 15 '25	Sale	75.42	27,000	2,036,325	249,062	Aug 19 04:30 PM
Pelish Henry E.	Chief Scientific Officer	Aug 07 '25	Option Exercise	27.71	5,500	152,415	66,456	Aug 08 04:30 PM
Pelish Henry E.	Chief Scientific Officer	Aug 07 '25	Sale	74.85	5,500	411,675	60,956	Aug 08 04:30 PM
Noci Darlene	Chief Development Officer	Jul 30 '25	Option Exercise	27.85	4,000	111,400	52,034	Aug 01 04:30 PM
Noci Darlene	Chief Development Officer	Jul 30 '25	Sale	80.36	4,000	321,440	48,034	Aug 01 04:30 PM
BCLS II INVESTCO, LP	Former Affiliate	Jul 24 '25	Proposed Sale	82.08	4,253	349,086		Jul 24 08:42 PM
BCIP Life Sciences Associates,	Former Affiliate	Jul 24 '25	Proposed Sale	82.08	156,670	12,859,474		Jul 24 08:35 PM
Bain Capital Life Sciences Fun	Former Affiliate	Jul 24 '25	Proposed Sale	82.08	1,286,344	105,583,116		Jul 24 08:31 PM
Balcom Alexandra	Chief Financial Officer	Jul 16 '25	Option Exercise	18.93	14,700	278,271	76,434	Jul 17 04:32 PM
Balcom Alexandra	Chief Financial Officer	Jul 15 '25	Option Exercise	18.93	5,300	100,329	67,034	Jul 17 04:32 PM
Balcom Alexandra	Chief Financial Officer	Jul 16 '25	Sale	85.10	14,700	1,250,970	61,734	Jul 17 04:32 PM
Balcom Alexandra	Chief Financial Officer	Jul 15 '25	Sale	83.50	5,300	442,526	61,734	Jul 17 04:32 PM
Porter James Richard	President and CEO	Jul 15 '25	Option Exercise	18.93	27,000	511,110	276,062	Jul 17 04:31 PM
Porter James Richard	President and CEO	Jul 15 '25	Sale	82.27	27,000	2,221,419	249,062	Jul 17 04:31 PM
James Richard Porter	Officer	Jul 15 '25	Proposed Sale	84.59	81,000	6,851,790		Jul 15 04:01 PM
Pelish Henry E.	Chief Scientific Officer	Jul 10 '25	Option Exercise	28.75	5,500	158,123	66,456	Jul 11 04:30 PM
Pelish Henry E.	Chief Scientific Officer	Jul 10 '25	Sale	79.98	5,500	439,905	60,956	Jul 11 04:30 PM
Pelish Henry E.	Chief Scientific Officer	Jul 09 '25	Sale	81.16	2,145	174,081	60,956	Jul 11 04:30 PM
Henry E. Pelish	Officer	Jul 09 '25	Proposed Sale	81.15	2,145	174,076		Jul 09 06:06 PM
Balcom Alexandra	Chief Financial Officer	Jun 27 '25	Option Exercise	18.93	20,000	378,600	81,734	Jul 01 04:30 PM
Balcom Alexandra	Chief Financial Officer	Jun 27 '25	Sale	80.02	20,000	1,600,400	61,734	Jul 01 04:30 PM
Noci Darlene	Chief Development Officer	Jun 26 '25	Option Exercise	27.85	4,000	111,400	52,034	Jun 27 05:07 PM
Noci Darlene	Chief Development Officer	Jun 26 '25	Sale	78.71	4,000	314,826	48,034	Jun 27 05:07 PM
Pelish Henry E.	Chief Scientific Officer	Jun 25 '25	Option Exercise	28.70	8,630	247,676	71,731	Jun 27 05:05 PM
Pelish Henry E.	Chief Scientific Officer	Jun 27 '25	Option Exercise	29.09	2,170	63,133	65,271	Jun 27 05:05 PM
Pelish Henry E.	Chief Scientific Officer	Jun 25 '25	Sale	79.87	8,630	689,278	63,101	Jun 27 05:05 PM
Pelish Henry E.	Chief Scientific Officer	Jun 27 '25	Sale	79.92	2,170	173,426	63,101	Jun 27 05:05 PM
Alexandra Balcom	Officer	Jun 27 '25	Proposed Sale	80.00	129,480	10,358,400		Jun 27 04:18 PM
Darlene Noci	Officer	Jun 26 '25	Proposed Sale	79.07	12,000	948,840		Jun 26 04:03 PM
Porter James Richard	President and CEO	Jun 16 '25	Option Exercise	27.85	27,000	751,950	276,062	Jun 17 04:31 PM
Porter James Richard	President and CEO	Jun 16 '25	Sale	76.93	27,000	2,077,093	249,062	Jun 17 04:31 PM
Pelish Henry E.	Chief Scientific Officer	Jun 06 '25	Option Exercise	28.59	200	5,718	63,301	Jun 10 04:38 PM
Pelish Henry E.	Chief Scientific Officer	Jun 06 '25	Sale	79.82	200	15,964	63,101	Jun 10 04:38 PM
HENRY E PELISH	Officer	Jun 06 '25	Proposed Sale	78.09	22,000	1,717,980		Jun 06 04:24 PM
Noci Darlene	Chief Development Officer	May 29 '25	Option Exercise	20.69	4,000	82,765	52,034	May 30 04:31 PM
Noci Darlene	Chief Development Officer	May 29 '25	Sale	71.31	4,000	285,236	48,034	May 30 04:31 PM
Porter James Richard	President and CEO	May 15 '25	Option Exercise	27.85	27,000	751,950	276,062	May 16 04:30 PM

Open in Screener

LRMR

Larimar Therapeutics Inc

Nov 25 • 04:00PM ET

3.67

+0.01 0.27 %

Healthcare • Biotechnology • USA • NASD

LRMR Larimar Therapeutics Inc daily Stock Chart

Peers: VRTX BMRN FOLD QURE RPTX ARWR ONCT SRPT CRSP RIGL

| Held by: VTI IWM VXF IWN IBB VTWO IWC AVSC DFAS VTWV

Index	RUT	P/E	-	EPS (ttm)	-1.93	Insider Own	44.26%	Shs Outstand	85.59M	Perf Week	8.26%
Market Cap	314.12M	Forward P/E	-	EPS next Y	-1.88	Insider Trans	32.89%	Shs Float	47.71M	Perf Month	-15.44%
Enterprise Value	143.03M	PEG	-	EPS next Q	-0.50	Inst Own	57.32%	Short Float	19.08%	Perf Quarter	-5.90%
Income	-132.00M	P/S	-	EPS this Y	-48.77%	Inst Trans	15.94%	Short Ratio	3.58	Perf Half Y	84.42%
Sales	0.00M	P/B	2.26	EPS next Y	4.51%	ROA	-64.96%	Short Interest	9.10M	Perf YTD	-5.17%
Book/sh	1.62	P/C	1.79	EPS next 5Y	-6.92%	ROE	-78.24%	52W High	6.91 -46.89%	Perf Year	-40.13%
Cash/sh	2.05	P/FCF	-	EPS past 3/5Y	23.60% 50.78%	ROIC	-92.80%	52W Low	1.61 127.95%	Perf 3Y	19.54%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.23% 8.04%	Perf 5Y	-82.70%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-67.41%	Oper. Margin	-	ATR (14)	0.29	Perf 10Y	-97.89%
Dividend Ex-Date	-	Quick Ratio	4.06	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	49.00	Recom	1.09
Dividend Gr. 3/5Y	- -	Current Ratio	4.06	EPS Q/Q	-150.80%	SMA20	2.03%	Beta	1.06	Target Price	16.70
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	-9.12%	Rel Volume	0.59	Prev Close	3.66
Employees	65	LT Debt/Eq	0.02	Earnings	Nov 05 BMO	SMA200	15.12%	Avg Volume	2.55M	Price	3.67
IPO	Jun 19, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	-51.10% -	Trades		Volume	1,503,108	Change	0.27%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-29-25	Initiated	Truist	Buy	$18
Oct-16-24	Initiated	Oppenheimer	Outperform	$26
Oct-03-24	Initiated	Wedbush	Outperform	$22
Oct-02-24	Initiated	H.C. Wainwright	Buy	$15
Sep-04-24	Initiated	Robert W. Baird	Outperform	$16
Apr-03-24	Initiated	Leerink Partners	Outperform	$25
Nov-17-23	Upgrade	Citigroup	Neutral → Buy	$4.50
Oct-19-22	Initiated	Guggenheim	Buy	$12
Feb-15-22	Downgrade	William Blair	Outperform → Mkt Perform
Feb-10-21	Initiated	JMP Securities	Mkt Outperform
Feb-01-21	Initiated	William Blair	Outperform	$29

Show Previous Ratings

Nov-05-25 07:14AM	Larimar: Q3 Earnings Snapshot (Associated Press Finance) -15.26%
07:00AM	Larimar Therapeutics Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-22-25 05:47PM	The Best AI for Picking Stocks, Ranked by Performance (MarketBeat) -8.39%
Oct-09-25 04:14PM	Lost Money on Larimar Therapeutics, Inc. (LRMR)? Possible Fraud - Contact Levi & Korsinsky Today (Newsfile) -5.60%
Sep-29-25 07:00AM	Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich's Ataxia (GlobeNewswire) -33.66%
05:00PM	Loading…
Sep-28-25 05:00PM	Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia (GlobeNewswire)
Aug-14-25 07:13AM	Larimar: Q2 Earnings Snapshot (Associated Press Finance) +14.52%
07:00AM	Larimar Therapeutics Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-31-25 04:15PM	Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Jul-29-25 11:50PM	Larimar Therapeutics Announces Pricing of Underwritten Public Offering (GlobeNewswire)
04:01PM	Larimar Therapeutics Announces Proposed Underwritten Public Offering (GlobeNewswire)
Jul-17-25 09:11AM	Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics (Zacks)
Jul-16-25 09:01AM	5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats (Zacks)
Jul-08-25 07:00AM	Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich's Ataxia (GlobeNewswire)
Jun-23-25 07:00AM	Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich's Ataxia Program (GlobeNewswire) -6.56%
04:05PM	Loading…
Jun-20-25 04:05PM	Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia (GlobeNewswire) -5.47%
May-21-25 11:22AM	Larimar Therapeutics, Inc.'s (LRMR): Analysts See 957% Upside Potential (Insider Monkey) -6.31%
Apr-30-25 07:00AM	Larimar Therapeutics Reports First Quarter 2025 Financial Results (GlobeNewswire) +10.88%
Apr-04-25 01:12PM	Larimar Therapeutics: Initiating Hold Rating With Upcoming Catalysts (Seeking Alpha)
Mar-24-25 07:00AM	Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire) -10.24%
Mar-03-25 04:05PM	Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference (GlobeNewswire) -12.54% +5.28%
Jan-23-25 04:05PM	Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's Ataxia (GlobeNewswire)
Dec-17-24 07:20AM	Larimar Therapeutics announces initial data from OLE study of nomlabofusp (TipRanks) -10.56%
Dec-16-24 07:00AM	Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study and Progress Across Nomlabofusp Program for Friedreich's Ataxia (GlobeNewswire) -21.72%
07:00AM	Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreichs Ataxia (GlobeNewswire)
Nov-18-24 07:00AM	Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024 (GlobeNewswire) -7.92%
Oct-30-24 07:00AM	Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results (GlobeNewswire) +8.74%
Sep-19-24 07:00AM	Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research (GlobeNewswire)
Aug-27-24 08:00AM	Larimar Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-07-24 07:00AM	Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results (GlobeNewswire) -6.54%
04:05PM	Loading…
May-30-24 04:05PM	Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich's Ataxia (GlobeNewswire) +12.68%
May-22-24 11:25AM	Larimar (LRMR) Up on Lifting of Partial Clinical Hold on FA Study (Zacks)
May-21-24 07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace) +8.53%
May-20-24 04:05PM	Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich's Ataxia (GlobeNewswire)
May-09-24 01:55PM	LRMR Stock Earnings: Larimar Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
07:00AM	Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results (GlobeNewswire)
Mar-20-24 01:32PM	Billionaire Steve Cohen and Insiders Are Buying These 10 Stocks (Insider Monkey)
Mar-14-24 09:53PM	LRMR Stock Earnings: Larimar Therapeutics Misses EPS for Q4 2023 (InvestorPlace) -6.51%
05:32PM	Larimar Therapeutics Inc (LRMR) Reports Full Year and Q4 2023 Financial Results (GuruFocus.com)
04:05PM	Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development (GlobeNewswire)
Mar-11-24 04:05PM	Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich's Ataxia (GlobeNewswire) -15.39%
Mar-06-24 04:05PM	Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference (GlobeNewswire)
Feb-20-24 01:47PM	Hedge Fund and Insider Trading News: Bill Ackman, George Soros, Arkhouse Management, TYR Capital, Borea Asset Management, Larimar Therapeutics, Inc. (LRMR), and More (Insider Monkey) -5.63%
Feb-19-24 01:48PM	Hedge Fund and Insider Trading News: Bill Ackman, David Tepper, Mark Yusko, Elliott Management, Conestoga Capital Advisors, Larimar Therapeutics Inc (LRMR), Agree Realty Corporation (ADC), and More (Insider Monkey)
Feb-16-24 04:20PM	Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -5.63%
Feb-14-24 06:15AM	Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock (GlobeNewswire) +36.84%
Feb-13-24 04:18PM	Larimar Therapeutics Announces Proposed Underwritten Public Offering (GlobeNewswire) +11.62%
Feb-12-24 07:00AM	Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich's Ataxia (GlobeNewswire)
Nov-14-23 07:00AM	Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results (GlobeNewswire) +7.11%
Nov-01-23 04:05PM	Larimar Therapeutics to Present at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference (GlobeNewswire)
Oct-03-23 04:05PM	Larimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of Directors (GlobeNewswire) -5.83%
Aug-31-23 04:05PM	Larimar Therapeutics to Present at the Citi 18th Annual BioPharma Conference (GlobeNewswire)
Aug-10-23 07:00AM	Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results (GlobeNewswire)
Aug-07-23 09:22AM	Larimar Therapeutics Insiders Placed Bullish Bets Worth US$1.2m (Simply Wall St.) -7.19%
Jul-25-23 09:59AM	These 2 Strong Buy Penny Stocks Could Go Boom, Say Analysts (TipRanks) +7.67%
07:00AM	Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601s Phase 2 Friedreich's Ataxia Trial and to Initiate Open Label Extension Trial (GlobeNewswire)
Jul-17-23 04:05PM	Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer (GlobeNewswire)
Jun-21-23 04:05PM	Larimar Therapeutics Set to Join Russell 3000® Index (GlobeNewswire)
May-15-23 07:00AM	Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trials 25 mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreichs Ataxia and First Quarter 2023 Financial Results (GlobeNewswire) -29.05%
Mar-28-23 04:05PM	Larimar Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Days (GlobeNewswire)
Mar-14-23 07:00AM	Larimar Therapeutics Reports Fourth Quarter and Full Year 2022 Operating and Financial Results (GlobeNewswire)
Feb-07-23 04:05PM	Larimar Therapeutics Appoints Dr. Gopi Shankar as Chief Development Officer (GlobeNewswire) +6.52% +7.99%
Nov-21-22 04:05PM	Larimar Therapeutics to Present at the 34th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-10-22 07:00AM	Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results (GlobeNewswire)
Nov-07-22 04:05PM	Larimar Therapeutics to Participate in the Guggenheim 4th Annual Immunology & Neurology Day (GlobeNewswire)
Oct-20-22 08:00AM	Larimar Therapeutics Announces Issuance of U.S. Patent Providing Composition of Matter Protection for CTI-1601 (GlobeNewswire)
Oct-19-22 04:05PM	Larimar Therapeutics Announces Oral and Poster Presentations at the Upcoming International Congress for Ataxia Research (GlobeNewswire)
Sep-16-22 01:00PM	Larimar Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Option to Purchase Additional Shares (GlobeNewswire) -5.04%
Sep-14-22 07:04AM	Larimar Therapeutics Announces $70 Million Underwritten Offering (GlobeNewswire) +15.56%
07:01AM	Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreichs Ataxia Patients (GlobeNewswire)
Aug-11-22 04:05PM	Larimar Therapeutics Provides Updates on CTI-1601 Clinical Program Following a Type C Meeting with the U.S. Food and Drug Administration and Reports Second Quarter 2022 Operating and Financial Results (GlobeNewswire) +7.07%
Jul-28-22 04:05PM	Larimar Therapeutics Announces Presentation at the Upcoming Gordon Research Conference on Neurobiology of Brain Disorders (GlobeNewswire)
Jun-28-22 08:00AM	Larimar Therapeutics Announces Oral Presentation at the Upcoming Gordon Research Conference on Mitochondria and Chloroplasts (GlobeNewswire)
06:05AM	We're Keeping An Eye On Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Rate (Simply Wall St.)
Jun-02-22 08:00AM	Larimar Therapeutics Announces Upcoming Scientific Conference Presentations (GlobeNewswire)
May-19-22 08:00AM	Larimar Therapeutics Announces Upcoming Poster Presentations at the 4th Pan American Parkinsons Disease and Movement Disorders Congress (GlobeNewswire)
May-12-22 07:00AM	Larimar Therapeutics Reports First Quarter 2022 Operating and Financial Results (GlobeNewswire) -7.91%
Apr-29-22 06:27AM	Despite recent gains, Larimar Therapeutics, Inc. (NASDAQ:LRMR) insiders are still down US$273k after purchasing last year (Simply Wall St.) -5.84%
Apr-13-22 10:40AM	Down 21.2% in 4 Weeks, Here's Why You Should You Buy the Dip in Larimar (LRMR) (Zacks)
Mar-25-22 07:00AM	Larimar Therapeutics Reports Fourth Quarter and Full Year 2021 Operating and Financial Results (GlobeNewswire)
Feb-16-22 11:57AM	Larimar Therapeutics' stock plunges on FDA decision; could implement cost-cutting measures (American City Business Journals)
Feb-14-22 04:01PM	Larimar Therapeutics Provides Update on CTI-1601 Clinical Program (GlobeNewswire) -52.09%
Jan-19-22 06:53AM	Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Nov-22-21 07:00AM	Larimar Therapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference (GlobeNewswire)
Nov-20-21 08:40AM	In spite of Larimar Therapeutics, Inc.'s recent pullback, insiders still gained about US$85k after buying earlier this year. (Simply Wall St.)
Nov-15-21 07:00AM	Larimar Therapeutics to Participate in the Guggenheim Virtual Neuro/Immunology Conference (GlobeNewswire)
Nov-12-21 07:00AM	Larimar Therapeutics Reports Third Quarter 2021 Operating and Financial Results (GlobeNewswire) -8.72%
Sep-16-21 08:00AM	Larimar Therapeutics to Participate in SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines Event (GlobeNewswire) -7.48%
Sep-02-21 04:01PM	Larimar Therapeutics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference (GlobeNewswire) +5.81%
Aug-22-21 10:12AM	What You Need To Know About Larimar Therapeutics, Inc.'s (NASDAQ:LRMR) Investor Composition (Simply Wall St.)
Aug-19-21 07:00AM	Larimar Therapeutics Announces Upcoming Oral Presentation at the World Orphan Drug Congress (GlobeNewswire)
Aug-12-21 07:00AM	Larimar Therapeutics Reports Second Quarter 2021 Operating and Financial Results (GlobeNewswire) +17.79%
Aug-09-21 08:48AM	Why Larimar (LRMR) Might Surprise This Earnings Season (Zacks)
Jul-23-21 12:00PM	Larimar (LRMR) Upgraded to Buy: Here's Why (Zacks)
Jul-08-21 04:01PM	Larimar Therapeutics to Present at the William Blair Biotech Focus Conference 2021 (GlobeNewswire)
Jun-11-21 07:00AM	Larimar Therapeutics to Present at the JMP Securities Life Sciences Conference (GlobeNewswire)
Jun-05-21 07:55PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR (Newsfile)
Jun-02-21 10:56PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR (GlobeNewswire)
Jun-01-21 04:55AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR (PR Newswire)
May-29-21 10:59PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR (Newsfile)

Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Flynn James E	Director	Jul 31 '25	Buy	3.20	9,375,000	30,000,000	9,538,945	Aug 04 06:28 PM

Open in Screener

SPRY

ARS Pharmaceuticals Inc

Nov 25 • 04:00PM ET

9.28

+1.25 15.57 %

Healthcare • Biotechnology • USA • NASD

SPRY ARS Pharmaceuticals Inc daily Stock Chart

Peers: ALNY IONS RNA ARWR SRPT NBIX ENTA VRTX RARE ASND

| Held by: VTI XBI IWM VXF IWO IBB VTWO SCHA USVM VHT

Index	RUT	P/E	-	EPS (ttm)	-0.81	Insider Own	39.58%	Shs Outstand	98.84M	Perf Week	30.98%
Market Cap	917.31M	Forward P/E	-	EPS next Y	-1.29	Insider Trans	-2.66%	Shs Float	59.72M	Perf Month	-2.93%
Enterprise Value	726.86M	PEG	-	EPS next Q	-0.42	Inst Own	64.44%	Short Float	33.08%	Perf Quarter	-30.95%
Income	-80.04M	P/S	6.43	EPS this Y	-2241.67%	Inst Trans	2.10%	Short Ratio	7.56	Perf Half Y	-37.51%
Sales	142.77M	P/B	6.21	EPS next Y	24.71%	ROA	-27.11%	Short Interest	19.76M	Perf YTD	-12.04%
Book/sh	1.49	P/C	3.18	EPS next 5Y	-	ROE	-45.92%	52W High	18.90 -50.90%	Perf Year	-30.64%
Cash/sh	2.92	P/FCF	-	EPS past 3/5Y	- -	ROIC	-32.69%	52W Low	6.66 39.34%	Perf 3Y	53.39%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	152.98% -	Gross Margin	89.29%	Volatility	11.25% 9.05%	Perf 5Y	-
Dividend TTM	-	EV/Sales	5.09	EPS Y/Y TTM	-59.70%	Oper. Margin	-63.59%	ATR (14)	0.73	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.51	Sales Y/Y TTM	5459.66%	Profit Margin	-56.06%	RSI (14)	55.70	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	6.66	EPS Q/Q	-162.66%	SMA20	11.59%	Beta	0.84	Target Price	28.67
Payout	0.00%	Debt/Eq	0.66	Sales Q/Q	1471.62%	SMA50	-1.16%	Rel Volume	1.48	Prev Close	8.03
Employees	160	LT Debt/Eq	0.66	Earnings	Nov 10 BMO	SMA200	-28.07%	Avg Volume	2.61M	Price	9.28
IPO	Dec 04, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-14.59% 13.35%	Trades		Volume	3,859,740	Change	15.57%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-04-25	Resumed	Roth Capital	Buy	$30
Sep-04-25	Initiated	Roth Capital	Buy	$40
Mar-07-25	Initiated	Scotiabank	Sector Outperform	$30
Feb-10-25	Initiated	Oppenheimer	Outperform	$40
Aug-20-24	Initiated	Cantor Fitzgerald	Overweight
Aug-13-24	Upgrade	Raymond James	Outperform → Strong Buy	$18 → $22
Aug-12-24	Reiterated	Leerink Partners	Outperform	$19 → $20
Jul-25-24	Initiated	Raymond James	Outperform	$18
Mar-05-24	Upgrade	Leerink Partners	Market Perform → Outperform	$6 → $18
Feb-20-24	Upgrade	William Blair	Mkt Perform → Outperform
Sep-20-23	Downgrade	William Blair	Outperform → Mkt Perform
Jan-31-23	Initiated	Wedbush	Outperform	$10
Jan-03-23	Initiated	William Blair	Outperform	$17
Dec-13-22	Initiated	SVB Leerink	Outperform	$14

Show Previous Ratings

Nov-10-25 04:01PM	ARS Pharmaceuticals Inc (SPRY) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic ... (GuruFocus.com)
07:05AM	ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
06:00AM	ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy (epinephrine nasal spray) (GlobeNewswire)
Nov-07-25 07:19AM	ARS Pharmaceuticals Inc (SPRY) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com) +7.99%
Nov-06-25 09:10AM	Lipocine (LPCN) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -9.45%
09:15AM	Loading…
Nov-05-25 09:15AM	NewAmsterdam Pharma Company N.V. (NAMS) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Nov-04-25 09:35AM	DraftKings, Flutter downgraded: Wall Street's top analyst calls (The Fly)
08:00AM	ARS Pharma Launches Get neffy on Us for Patients with Severe Allergic Reactions to Improve Access to neffy (epinephrine nasal spray) (GlobeNewswire)
Nov-03-25 02:23PM	UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting (GlobeNewswire)
08:00AM	ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results (GlobeNewswire)
07:45AM	ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting (GlobeNewswire)
Oct-08-25 08:00AM	ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy (epinephrine nasal spray) (GlobeNewswire) +7.55%
Sep-29-25 04:05PM	ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy (GlobeNewswire)
Sep-19-25 08:00AM	neffy (epinephrine nasal spray) Approved in Japan as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) (GlobeNewswire)
Sep-17-25 11:44AM	ARS Pharmaceuticals, Inc. (SPRY): A Bull Case Theory (Insider Monkey)
08:11AM	Loading…
Sep-09-25 08:11AM	ARS Pharmaceuticals announces real-world evidence on neffy effectiveness (TipRanks)
Sep-08-25 08:00AM	Real-World Evidence Supports Clinical Effectiveness of neffy (epinephrine nasal spray) in Patients Experiencing Anaphylaxis (GlobeNewswire) +6.26%
Sep-04-25 02:54PM	ARS Pharmaceuticals (SPRY) Faces Patent Test as Lupin Files ANDA (Insider Monkey)
Aug-28-25 08:00AM	ARS Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-13-25 08:15AM	ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Beats Revenue Estimates (Zacks) -5.04%
07:00AM	ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy (epinephrine nasal spray) (GlobeNewswire)
05:26AM	Cisco Systems headlines earnings slate (MarketWatch)
Aug-12-25 09:24AM	ARS Pharmaceuticals Inc (SPRY) Q2 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Aug-11-25 06:55PM	4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -6.40%
Aug-08-25 01:56PM	Paramount, Rocket, and More Stocks See Action From Activist Investors (Barrons.com)
Aug-04-25 08:00AM	ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-31-25 05:35PM	Corcept Therapeutics (CORT) Tops Q2 Earnings Estimates (Zacks)
08:50AM	Here's What Could Help ARS Pharmaceuticals, Inc. (SPRY) Maintain Its Recent Price Strength (Zacks)
Jul-30-25 10:00AM	Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Jul-29-25 10:00AM	Analysts Estimate ARS Pharmaceuticals, Inc. (SPRY) to Report a Decline in Earnings: What to Look Out for (Zacks)
12:27PM	Loading…
Jul-18-25 12:27PM	MHRA approves needle-free adrenaline nasal spray for anaphylaxis (Pharmaceutical Technology)
09:25AM	EURneffy (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) (GlobeNewswire)
Jul-15-25 12:00PM	ARS Pharmaceuticals, Inc. (SPRY) is a Great Momentum Stock: Should You Buy? (Zacks)
09:55AM	Wall Street Analysts See a 78.77% Upside in ARS Pharmaceuticals, Inc. (SPRY): Can the Stock Really Move This High? (Zacks)
08:50AM	What Makes ARS Pharmaceuticals, Inc. (SPRY) a Good Fit for 'Trend Investing' (Zacks)
Jun-15-25 05:26AM	Jim Cramer on ARS Pharmaceuticals: "It's a Great Flier" (Insider Monkey)
Jun-11-25 09:02PM	Lightning Round: I don't want to buy enterprise software right now, says Jim Cramer (CNBC TV)
May-27-25 08:00AM	ARS Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-15-25 03:12AM	ARS Pharmaceuticals Inc (SPRY) Q1 2025 Earnings Call Highlights: Strong Launch of Neffy Amid ... (GuruFocus.com)
May-14-25 10:44PM	Q1 2025 ARS Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -9.36%
08:15AM	ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy (epinephrine nasal spray) (GlobeNewswire)
May-13-25 09:28AM	ARS Pharmaceuticals Inc (SPRY) Q1 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
May-08-25 05:06AM	ARS Pharmas epinephrine nasal spray 1mg now available in US (Pharmaceutical Technology)
May-05-25 08:00AM	ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results (GlobeNewswire)
May-04-25 04:32PM	Aquestive Therapeutics: Unprofitable For A Few More Years, But Significant Upside Potential (Seeking Alpha)
May-02-25 08:00AM	ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians (GlobeNewswire)
08:00AM	ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abello A/S to Expand Reach of neffy (epinephrine nasal spray) to Additional U.S. Pediatricians (GlobeNewswire)
Apr-30-25 06:51AM	ARS Pharmaceuticals Has A Blockbuster Candidate (Seeking Alpha)
Apr-05-25 05:31PM	ARS Pharmaceuticals (SPRY): Among Unstoppable Stocks That Could Double Your Money (Insider Monkey)
Mar-23-25 07:18AM	Wall Street Week Ahead (SeekingAlpha)
Mar-21-25 12:16PM	Accenture reports Q2 beat, Apple TV+ losing $1B annually: Morning Buzz (TipRanks) -13.63%
12:03PM	ARS Pharmaceuticals Inc (SPRY) Q4 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
03:03AM	ARS Pharmaceuticals Inc (SPRY) Q4 2024 Earnings Call Highlights: Strong Financial Position and ... (GuruFocus.com)
12:40AM	Q4 2024 ARS Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-20-25 04:04PM	ARS Pharma Retakes Its 50-Day Line In Bullish Post-Earnings Move. Here's Why. (Investor's Business Daily) +22.83%
03:31PM	ARS Pharmaceuticals: Surging On Solid Earnings - But Real Challenges Await (SeekingAlpha)
01:29PM	ARS Pharmaceuticals outlines 2025 growth strategy with neffy commercialization and global expansion (SeekingAlpha)
01:28PM	ARS Pharmaceuticals, Inc. (SPRY) Q4 2024 Earnings Conference Call Transcript (SeekingAlpha)
08:25AM	ARS Pharmaceuticals, Inc. (SPRY) Q4 Earnings and Revenues Beat Estimates (Zacks)
07:00AM	ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-06-25 05:27AM	FDA approves ARS neffy 1mg for paediatric anaphylaxis (Pharmaceutical Technology)
Mar-03-25 04:35PM	ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences (GlobeNewswire)
Feb-20-25 07:02PM	ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients (GlobeNewswire)
Feb-18-25 08:00AM	ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting (GlobeNewswire)
Feb-05-25 08:00AM	ARS Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Conference (GlobeNewswire)
Jan-21-25 08:00AM	ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools (GlobeNewswire) +7.24%
Jan-13-25 04:15PM	BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps. (Investor's Business Daily)
08:00AM	ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy (epinephrine nasal spray) (GlobeNewswire)
Jan-07-25 08:15AM	ARS Pharmaceuticals files for approval of neffy in Canada, U.K. (TipRanks)
06:43AM	ARS Pharma seeks approval for epinephrine spray in Canada and UK (Medical Device Network)
Jan-06-25 08:00AM	ARS Pharmaceuticals Files for Approval of neffy in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abello A/S (GlobeNewswire)
08:00AM	ARS Pharmaceuticals Files for Approval of neffy in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abell A/S (GlobeNewswire)
Dec-19-24 05:25PM	ARS Pharmaceuticals Announces neffy (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies (GlobeNewswire)
Dec-18-24 08:00AM	ARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -6.80%
Dec-12-24 02:32PM	ARS Pharmaceuticals Announces Filings for Approval of neffy in China, Japan and Australia (GlobeNewswire)
Dec-04-24 08:00AM	ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost (GlobeNewswire) +5.95%
Nov-14-24 02:08AM	ARS Pharmaceuticals Inc (SPRY) Q3 2024 Earnings Call Highlights: Strong Cash Position and NEPHI ... (GuruFocus.com)
Nov-13-24 07:40AM	ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -15.23%
06:30AM	ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-12-24 07:06AM	ARS Pharmaceuticals announces agreement with ALK to commercialize neffy (TipRanks) -5.03%
Nov-11-24 04:02PM	ARS Pharma Jumps After Inking $145 Million Deal For Epinephrine Nasal Spray (Investor's Business Daily)
11:01AM	ALK snags EU and Canada rights to anaphylaxis nasal spray Neffy for $145m (Pharmaceutical Technology)
07:41AM	ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024 (Benzinga)
07:00AM	ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy in Europe, Canada and Other Geographies Outside the United States (GlobeNewswire)
Nov-09-24 05:30PM	ALK licenses rights to neffy , the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis) (GlobeNewswire)
Nov-06-24 09:55AM	Wall Street Analysts Think ARS Pharmaceuticals, Inc. (SPRY) Could Surge 67.56%: Read This Before Placing a Bet (Zacks)
08:00AM	ARS Pharmaceuticals Announces Conference Call and Webcasts for its Third Quarter 2024 Financial Results and Presentations at Upcoming Conferences (GlobeNewswire)
Oct-24-24 08:30AM	ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting (GlobeNewswire)
Oct-14-24 09:55AM	Wall Street Analysts Believe ARS Pharmaceuticals, Inc. (SPRY) Could Rally 76.79%: Here's is How to Trade (Zacks)
Sep-30-24 10:33AM	Neffy nasal spray: a game changer for asthma patients and epinephrine delivery? (Pharmaceutical Technology)
Sep-23-24 08:00AM	ARS Pharmaceuticals Announces U.S. Availability of neffy (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis (GlobeNewswire)
Sep-11-24 08:20AM	ARS Pharmaceuticals (SPRY): A Bull Case Theory (Insider Monkey)
Sep-10-24 04:05PM	ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference (GlobeNewswire)
Sep-09-24 04:47PM	ARS Pharmaceuticals Submits sNDA to FDA for neffy 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.) (GlobeNewswire)
Sep-06-24 12:00PM	ARS Pharmaceuticals, Inc. (SPRY) Upgraded to Buy: Here's Why (Zacks)
Sep-04-24 08:00AM	ARS Pharmaceuticals Launches Pre-Ordering Services for neffy to Help Patients Access the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis (GlobeNewswire)
Aug-27-24 10:08AM	Newly Approved ARS Pharmaceuticals' Needle-Free Neffy Offers Convenience Over EpiPen For Allergic Reaction, But Real-World Efficacy Questioned (UPDATED) (Benzinga) +5.76%
Aug-26-24 09:29AM	EURneffy (adrenaline nasal spray) Approved in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) (GlobeNewswire)
Aug-22-24 12:27AM	ARS Pharmaceuticals Inc (SPRY) CFO Kathleen Scott Sells 12,500 Shares (GuruFocus.com)

ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dorsey Brian	Chief Operating Officer	Nov 13 '25	Option Exercise	0.64	21,828	13,970	32,617	Nov 14 06:43 PM
Dorsey Brian	Chief Operating Officer	Nov 13 '25	Sale	8.71	21,828	190,050	10,789	Nov 14 06:43 PM
Chakma Justin	Chief Business Officer	Nov 12 '25	Option Exercise	0.84	30,000	25,200	166,380	Nov 14 06:42 PM
Chakma Justin	Chief Business Officer	Nov 12 '25	Sale	8.87	166,380	1,476,147	0	Nov 14 06:42 PM
BRIAN T DORSEY	Officer	Nov 13 '25	Proposed Sale	8.71	21,828	190,050		Nov 13 04:08 PM
JUSTIN CHAKMA	Officer	Nov 12 '25	Proposed Sale	8.91	30,000	267,357		Nov 12 05:26 PM
Chakma Justin	Officer	Nov 12 '25	Proposed Sale	8.87	138,380	1,227,420		Nov 12 10:56 AM
Lowenthal Richard E	PRESIDENT AND CEO	Aug 21 '25	Sale	14.49	50,000	724,345	1,196,494	Aug 22 04:30 PM
Scott Kathleen D.	Chief Financial Officer	Aug 21 '25	Option Exercise	1.50	12,500	18,750	22,542	Aug 22 04:30 PM
Scott Kathleen D.	Chief Financial Officer	Aug 21 '25	Sale	15.00	12,500	187,500	10,042	Aug 22 04:30 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Aug 20 '25	Sale	14.09	37,656	530,626	1,247,447	Aug 21 05:36 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Aug 19 '25	Sale	14.03	12,344	173,130	1,285,103	Aug 21 05:36 PM
KATHLEEN D SCOTT	Officer	Aug 21 '25	Proposed Sale	15.00	12,500	187,500		Aug 21 04:18 PM
Lowenthal Richard E	Officer	Aug 21 '25	Proposed Sale	14.15	150,000	2,123,000		Aug 21 11:20 AM
Tanimoto Sarina	Officer	Aug 19 '25	Proposed Sale	14.00	150,000	2,100,000		Aug 19 10:22 AM
Karas Eric	Chief Commercial Officer	Jul 01 '25	Option Exercise	1.50	15,000	22,500	25,315	Jul 03 04:21 PM
Karas Eric	Chief Commercial Officer	Jul 01 '25	Sale	16.99	15,000	254,860	10,315	Jul 03 04:21 PM
Flynn James E	10% Owner	Jun 27 '25	Sale	18.46	740,149	13,663,151	4,887,254	Jul 01 04:42 PM
ERIC KARAS	Officer	Jul 01 '25	Proposed Sale	16.99	15,000	254,859		Jul 01 04:20 PM
Karas Eric	Chief Commercial Officer	Jun 18 '25	Option Exercise	1.50	15,000	22,500	22,696	Jun 20 06:38 PM
Karas Eric	Chief Commercial Officer	Jun 18 '25	Sale	16.00	15,000	240,000	7,696	Jun 20 06:38 PM
ERIC KARAS	Officer	Jun 18 '25	Proposed Sale	16.00	15,000	240,000		Jun 18 04:51 PM
Fitzpatrick Alexander A	Chief Legal Officer	May 20 '25	Option Exercise	5.58	100,000	558,000	192,582	May 22 05:00 PM
Fitzpatrick Alexander A	Chief Legal Officer	May 20 '25	Sale	14.10	102,969	1,451,513	89,613	May 22 05:00 PM
SAUNDERS BRENT L	Director	May 20 '25	Option Exercise	1.01	120,000	121,200	120,000	May 22 05:00 PM
SAUNDERS BRENT L	Director	May 20 '25	Sale	14.25	120,000	1,710,024	0	May 22 05:00 PM
Scott Kathleen D.	Chief Financial Officer	May 20 '25	Option Exercise	1.50	50,000	75,000	57,424	May 22 05:00 PM
Scott Kathleen D.	Chief Financial Officer	May 20 '25	Sale	14.10	50,000	705,165	7,424	May 22 05:00 PM
Scott Kathleen D.	Officer	May 20 '25	Proposed Sale	14.10	50,000	705,000		May 20 05:24 PM
Fitzpatrick Alexander A	Officer	May 20 '25	Proposed Sale	14.02	102,969	1,443,894		May 20 04:50 PM
SAUNDERS BRENT L	Director	May 20 '25	Proposed Sale	14.25	120,000	1,710,000		May 20 04:48 PM
Shawver Laura	Director	Apr 07 '25	Option Exercise	4.85	50,002	242,510	260,348	Apr 08 04:45 PM
Shawver Laura	Director	Apr 07 '25	Sale	12.30	50,002	615,075	210,346	Apr 08 04:45 PM
Shawver Laura	Director	Apr 07 '25	Proposed Sale	12.30	50,002	615,051		Apr 07 02:26 PM
Karas Eric	Chief Commercial Officer	Mar 20 '25	Option Exercise	1.50	10,000	15,000	17,696	Mar 21 06:30 PM
Karas Eric	Chief Commercial Officer	Mar 20 '25	Sale	14.00	10,000	140,000	7,696	Mar 21 06:30 PM
ERIC KARAS	Officer	Mar 20 '25	Proposed Sale	14.00	10,000	140,000		Mar 20 04:03 PM
Shawver Laura	Director	Mar 06 '25	Option Exercise	4.85	49,600	240,560	259,946	Mar 07 05:12 PM
Shawver Laura	Director	Mar 05 '25	Option Exercise	4.85	400	1,940	210,746	Mar 07 05:12 PM
Shawver Laura	Director	Mar 06 '25	Sale	11.21	49,600	556,046	210,346	Mar 07 05:12 PM
Shawver Laura	Director	Mar 05 '25	Sale	11.00	400	4,400	210,346	Mar 07 05:12 PM
Shawver Laura	Director	Mar 05 '25	Proposed Sale	11.00	50,000	550,000		Mar 05 05:19 PM
Shawver Laura	Director	Feb 03 '25	Option Exercise	4.54	50,000	227,091	260,346	Feb 04 04:35 PM
Shawver Laura	Director	Feb 03 '25	Sale	12.31	50,000	615,565	210,346	Feb 04 04:35 PM
Shawver Laura	Director	Feb 03 '25	Proposed Sale	12.31	50,000	615,565		Feb 03 12:06 PM
Shawver Laura	Director	Jan 06 '25	Option Exercise	3.15	50,000	157,500	260,346	Jan 07 06:24 PM
Shawver Laura	Director	Jan 06 '25	Sale	11.10	50,000	555,065	210,346	Jan 07 06:24 PM
Shawver Laura	Director	Jan 06 '25	Proposed Sale	11.10	50,000	555,065		Jan 06 04:36 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Dec 17 '24	Sale	11.67	100,000	1,167,100	1,098,499	Dec 19 04:20 PM
Lowenthal Richard E	PRESIDENT AND CEO	Dec 17 '24	Sale	11.67	100,000	1,167,100	1,098,499	Dec 19 04:20 PM
Chakma Justin	Chief Business Officer	Dec 12 '24	Option Exercise	0.84	117,333	98,560	253,713	Dec 13 07:53 PM
Chakma Justin	Chief Business Officer	Dec 13 '24	Option Exercise	1.44	27,272	39,272	163,652	Dec 13 07:53 PM
Chakma Justin	Chief Business Officer	Dec 12 '24	Sale	12.27	117,333	1,439,124	136,380	Dec 13 07:53 PM
Chakma Justin	Chief Business Officer	Dec 13 '24	Sale	12.06	27,272	328,968	136,380	Dec 13 07:53 PM
Dorsey Brian	Chief Operating Officer	Dec 12 '24	Option Exercise	0.64	25,000	16,000	31,024	Dec 13 07:52 PM
Dorsey Brian	Chief Operating Officer	Dec 11 '24	Option Exercise	0.64	15,000	9,600	21,024	Dec 13 07:52 PM
Dorsey Brian	Chief Operating Officer	Dec 12 '24	Sale	12.30	25,000	307,432	6,024	Dec 13 07:52 PM
Dorsey Brian	Chief Operating Officer	Dec 11 '24	Sale	12.43	15,000	186,426	6,024	Dec 13 07:52 PM
Chakma Justin	Officer	Dec 13 '24	Proposed Sale	12.06	27,272	328,967		Dec 13 05:24 PM
Chakma Justin	Chief Business Officer	Dec 10 '24	Option Exercise	0.84	50,000	42,000	186,380	Dec 12 05:41 PM
Chakma Justin	Chief Business Officer	Dec 10 '24	Sale	13.15	50,000	657,625	136,380	Dec 12 05:41 PM
Chakma Justin	Officer	Dec 10 '24	Proposed Sale	11.50	117,333	1,349,330		Dec 12 05:02 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Dec 10 '24	Sale	13.16	100,000	1,316,420	1,148,499	Dec 11 06:30 PM
Lowenthal Richard E	PRESIDENT AND CEO	Dec 10 '24	Sale	13.16	100,000	1,316,420	1,148,499	Dec 11 06:30 PM
Dorsey Brian	Officer	Dec 11 '24	Proposed Sale	13.31	61,200	814,572		Dec 11 05:31 PM
Chakma Justin	Director	Dec 10 '24	Proposed Sale	14.02	50,000	701,000		Dec 10 04:48 PM
Lowenthal Richard E	Officer	Dec 10 '24	Proposed Sale	13.40	300,000	4,020,000		Dec 10 11:15 AM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Dec 06 '24	Option Exercise	4.67	25,665	119,852	3,433,512	Dec 09 05:43 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Dec 06 '24	Option Exercise	8.42	11,876	99,996	4,327,189	Dec 09 05:43 PM
Lowenthal Richard E	PRESIDENT AND CEO	Dec 06 '24	Option Exercise	4.67	25,665	119,852	3,433,512	Dec 09 05:25 PM
Lowenthal Richard E	PRESIDENT AND CEO	Dec 06 '24	Option Exercise	8.42	11,876	99,996	4,327,189	Dec 09 05:25 PM
Chakma Justin	Chief Business Officer	Dec 06 '24	Option Exercise	0.84	50,000	42,000	186,380	Dec 06 07:15 PM
Chakma Justin	Chief Business Officer	Dec 05 '24	Option Exercise	0.84	49,640	41,698	186,020	Dec 06 07:15 PM
Chakma Justin	Chief Business Officer	Dec 04 '24	Option Exercise	0.84	45,000	37,800	181,380	Dec 06 07:15 PM
Chakma Justin	Chief Business Officer	Dec 06 '24	Sale	14.23	50,000	711,615	136,380	Dec 06 07:15 PM
Chakma Justin	Chief Business Officer	Dec 05 '24	Sale	14.13	49,640	701,642	136,380	Dec 06 07:15 PM
Chakma Justin	Chief Business Officer	Dec 04 '24	Sale	13.95	45,000	627,944	136,380	Dec 06 07:15 PM
Chakma Justin	Officer	Dec 06 '24	Proposed Sale	14.00	50,000	700,000		Dec 06 05:30 PM
Chakma Justin	Officer	Dec 05 '24	Proposed Sale	13.32	49,640	661,205		Dec 05 05:06 PM
Chakma Justin	Chief Business Officer	Dec 02 '24	Option Exercise	0.84	45,000	37,800	181,380	Dec 04 09:45 PM
Chakma Justin	Chief Business Officer	Dec 03 '24	Option Exercise	0.84	45,000	37,800	181,380	Dec 04 09:45 PM
Chakma Justin	Chief Business Officer	Dec 02 '24	Sale	13.67	45,000	615,218	136,380	Dec 04 09:45 PM
Chakma Justin	Chief Business Officer	Dec 03 '24	Sale	13.19	45,000	593,402	136,380	Dec 04 09:45 PM
Shawver Laura	Director	Dec 03 '24	Option Exercise	2.60	87,984	229,010	298,330	Dec 04 09:40 PM
Shawver Laura	Director	Dec 02 '24	Option Exercise	1.27	97,244	123,500	307,590	Dec 04 09:40 PM
Shawver Laura	Director	Dec 04 '24	Option Exercise	3.15	14,772	46,532	225,118	Dec 04 09:40 PM
Shawver Laura	Director	Dec 02 '24	Sale	13.56	97,244	1,318,745	210,346	Dec 04 09:40 PM
Shawver Laura	Director	Dec 03 '24	Sale	13.26	87,984	1,166,897	210,346	Dec 04 09:40 PM
Shawver Laura	Director	Dec 04 '24	Sale	13.75	14,772	203,109	210,346	Dec 04 09:40 PM
Karas Eric	Chief Commercial Officer	Dec 04 '24	Option Exercise	1.50	6,283	9,424	11,976	Dec 04 09:40 PM
Karas Eric	Chief Commercial Officer	Dec 02 '24	Option Exercise	1.50	3,717	5,576	9,410	Dec 04 09:40 PM
Karas Eric	Chief Commercial Officer	Dec 04 '24	Sale	14.00	6,283	87,962	5,693	Dec 04 09:40 PM
Karas Eric	Chief Commercial Officer	Dec 02 '24	Sale	14.11	3,717	52,461	5,693	Dec 04 09:40 PM
ERIC KARAS	Officer	Dec 04 '24	Proposed Sale	14.00	6,283	87,962		Dec 04 05:46 PM
Chakma Justin	Officer	Dec 04 '24	Proposed Sale	14.51	45,000	652,950		Dec 04 05:15 PM
Chakma Justin	Officer	Dec 03 '24	Proposed Sale	13.00	45,000	585,000		Dec 03 05:25 PM
Chakma Justin	Officer	Dec 02 '24	Proposed Sale	14.51	45,000	652,950		Dec 02 07:01 PM
Shawver Laura	Director	Dec 02 '24	Proposed Sale	13.56	200,000	2,713,000		Dec 02 06:22 PM
ERIC KARAS	Officer	Dec 02 '24	Proposed Sale	14.11	3,717	52,461		Dec 02 04:42 PM
Chakma Justin	Chief Business Officer	Nov 26 '24	Sale	14.05	42,186	592,570	161,380	Nov 27 04:11 PM

Open in Screener

BCAX

Bicara Therapeutics Inc

Nov 25 • 04:00PM ET

18.46

-0.42 -2.22 %

Healthcare • Biotechnology • USA • NASD

BCAX Bicara Therapeutics Inc daily Stock Chart

Held by: VTI IWM VXF IWN SCHA VTWO FESM VHT ITOT TMSL

Index	RUT	P/E	-	EPS (ttm)	-2.23	Insider Own	41.48%	Shs Outstand	54.61M	Perf Week	18.56%
Market Cap	1.01B	Forward P/E	-	EPS next Y	-3.05	Insider Trans	-1.28%	Shs Float	32.06M	Perf Month	8.59%
Enterprise Value	723.08M	PEG	-	EPS next Q	-0.69	Inst Own	63.94%	Short Float	20.14%	Perf Quarter	53.58%
Income	-121.52M	P/S	-	EPS this Y	37.50%	Inst Trans	-1.99%	Short Ratio	10.28	Perf Half Y	95.14%
Sales	0.00M	P/B	2.50	EPS next Y	-20.46%	ROA	-25.61%	Short Interest	6.46M	Perf YTD	5.97%
Book/sh	7.38	P/C	3.49	EPS next 5Y	9.91%	ROE	-26.64%	52W High	22.67 -18.59%	Perf Year	3.88%
Cash/sh	5.30	P/FCF	-	EPS past 3/5Y	-30.70% -	ROIC	-30.10%	52W Low	7.80 136.67%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.90% 8.18%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	1.25	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	14.14	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	64.49	Recom	1.22
Dividend Gr. 3/5Y	- -	Current Ratio	14.14	EPS Q/Q	-107.22%	SMA20	18.09%	Beta	-1.05	Target Price	32.57
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	18.38%	Rel Volume	1.81	Prev Close	18.88
Employees	55	LT Debt/Eq	0.00	Earnings	Nov 10 BMO	SMA200	43.43%	Avg Volume	628.36K	Price	18.46
IPO	Sep 13, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	-23.82% -	Trades		Volume	1,136,579	Change	-2.22%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-19-25	Initiated	Piper Sandler	Overweight	$36
May-23-25	Upgrade	Wells Fargo	Underweight → Equal Weight	$8
Apr-17-25	Initiated	Wells Fargo	Underweight	$8
Feb-06-25	Initiated	Wedbush	Outperform	$31
Dec-06-24	Initiated	H.C. Wainwright	Buy	$42
Nov-05-24	Initiated	Rodman & Renshaw	Buy	$48
Oct-08-24	Initiated	TD Cowen	Buy
Oct-08-24	Initiated	Stifel	Buy	$47
Oct-08-24	Initiated	Morgan Stanley	Overweight	$35
Oct-08-24	Initiated	Cantor Fitzgerald	Overweight

Nov-10-25 07:30AM	Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Oct-27-25 08:30AM	Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology (PR Newswire)
Oct-13-25 07:30AM	Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC (GlobeNewswire)
Aug-27-25 04:01PM	Bicara Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-14-25 09:55AM	Does Bicara Therapeutics Inc. (BCAX) Have the Potential to Rally 187.73% as Wall Street Analysts Expect? (Zacks)
07:30AM	Loading…
Aug-12-25 07:30AM	Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jun-11-25 04:05PM	Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors (GlobeNewswire) -5.56%
Jun-03-25 04:01PM	Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire) +11.21%
Jun-01-25 01:12PM	Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025 (GlobeNewswire)
May-29-25 06:54AM	ASCO25: Merus wins in head-to-head with Bicara for head and neck cancer (Clinical Trials Arena)
May-27-25 01:59PM	Morgan Stanley Maintains Buy Rating on Bicara (BCAX) After the Ficerafusp Alfa Trial Update (Insider Monkey) +7.66%
May-26-25 09:14AM	Stifel Reaffirms Buy Rating on BCAX After Promising ASCO Data for HPV-Negative Patients (Insider Monkey)
May-23-25 10:15AM	Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics (Investor's Business Daily) -40.80%
May-22-25 05:00PM	Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting (GlobeNewswire) +7.33%
May-13-25 07:30AM	Bicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) -8.10%
04:01PM	Loading…
Apr-28-25 04:01PM	Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025 (GlobeNewswire)
Apr-23-25 10:00AM	Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) +12.23%
Apr-19-25 06:22AM	Bicara: Innovative Precision Tumor Targeting (Seeking Alpha)
Mar-27-25 07:30AM	Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Mar-25-25 04:45PM	Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025 (GlobeNewswire) -5.58%
Feb-24-25 04:01PM	Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-11-25 04:01PM	Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (GlobeNewswire)
Jan-27-25 08:00AM	Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium (GlobeNewswire)
Jan-08-25 10:16AM	Early success for MBX in Phase I trial of GLP-1RA for hypoglycaemia (Clinical Trials Arena)
Nov-12-24 07:30AM	Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -7.30%
Nov-11-24 04:01PM	Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference (GlobeNewswire)
Oct-14-24 06:45AM	Opening Day: Another trio of biotech IPOs make Friday debut (TipRanks)
Oct-08-24 10:44AM	MBX Biosciences earns Buy rating at three investment firms (Investing.com) -7.77%
Sep-23-24 07:05PM	RA Capital Management's Strategic Acquisition of Bicara Therapeutics Shares (GuruFocus.com)
Sep-19-24 01:13AM	TPG GP A, LLC Acquires New Stake in Bicara Therapeutics Inc (GuruFocus.com)
03:01PM	Loading…
Sep-18-24 03:01PM	FMR LLC Acquires New Stake in Bicara Therapeutics Inc (GuruFocus.com)
Sep-17-24 09:13AM	Bicara Therapeutics closes $362m IPO in flurry of biotech listing activity (Pharmaceutical Technology) +6.53%
Sep-16-24 04:01PM	Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) +8.54%
Sep-13-24 04:09PM	Biotech IPO Shares Climb in Debuts After Deals Upsized (Bloomberg)
12:19AM	Bicara Leads Trio of US Biotech IPOs Raising $703 Million (Bloomberg)
Sep-12-24 09:15PM	Bicara Therapeutics Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)
07:02PM	Three biotechs raise $700M in rare burst of IPO activity (BioPharma Dive)

Bicara Therapeutics, Inc. is a clinical-stage biotechnology company and develops biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The company's bi-functional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Its products include BCA101, a first-in-class EGFR/TGF-ß-trap bifunctional antibody in clinical development for multiple tumor types. The company was founded on December 12, 2018 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hyep Ivan	Chief Financial Officer	Nov 24 '25	Option Exercise	3.79	17,795	67,439	163,150	Nov 25 06:42 PM
Hyep Ivan	Chief Financial Officer	Nov 21 '25	Option Exercise	3.79	605	2,293	145,960	Nov 25 06:42 PM
Hyep Ivan	Chief Financial Officer	Nov 24 '25	Sale	18.55	17,795	330,094	145,355	Nov 25 06:42 PM
Hyep Ivan	Chief Financial Officer	Nov 21 '25	Sale	18.15	605	10,981	145,355	Nov 25 06:42 PM
Cohlhepp Ryan	President and COO	Nov 21 '25	Option Exercise	3.79	8,000	30,318	206,141	Nov 25 06:41 PM
Cohlhepp Ryan	President and COO	Nov 21 '25	Sale	18.05	12,500	225,588	193,641	Nov 25 06:41 PM
Mazumdar Claire	Chief Executive Officer	Nov 24 '25	Option Exercise	3.79	41,163	156,000	351,055	Nov 25 06:40 PM
Mazumdar Claire	Chief Executive Officer	Nov 24 '25	Sale	18.86	41,163	776,429	309,892	Nov 25 06:40 PM
Raben David	Chief Medical Officer	Nov 24 '25	Option Exercise	3.79	5,500	20,844	40,997	Nov 25 06:39 PM
Raben David	Chief Medical Officer	Nov 25 '25	Option Exercise	3.79	5,500	20,844	40,091	Nov 25 06:39 PM
Raben David	Chief Medical Officer	Nov 25 '25	Sale	18.84	5,500	103,633	35,497	Nov 25 06:39 PM
Raben David	Chief Medical Officer	Nov 24 '25	Sale	18.45	5,500	101,475	35,497	Nov 25 06:39 PM
Raben David	Officer	Nov 25 '25	Proposed Sale	18.84	5,500	103,633		Nov 25 04:29 PM
Mazumdar Claire	Officer	Nov 24 '25	Proposed Sale	18.86	41,163	776,429		Nov 24 04:24 PM
Hyep Ivan	Officer	Nov 24 '25	Proposed Sale	18.55	17,795	330,094		Nov 24 04:10 PM
Raben David	Officer	Nov 24 '25	Proposed Sale	18.45	5,500	101,475		Nov 24 04:09 PM
Hyep Ivan	Officer	Nov 21 '25	Proposed Sale	18.15	605	10,981		Nov 21 04:33 PM
Cohlhepp Ryan	Officer	Nov 21 '25	Proposed Sale	18.05	12,500	225,588		Nov 21 04:32 PM
Cohlhepp Ryan	President and COO	Oct 15 '25	Option Exercise	3.79	8,000	30,318	210,641	Oct 16 04:41 PM
Cohlhepp Ryan	President and COO	Oct 15 '25	Sale	18.16	12,500	226,942	198,141	Oct 16 04:41 PM
Mazumdar Claire	Officer	Oct 16 '25	Proposed Sale	18.83	24,103	453,761		Oct 16 04:13 PM
Mazumdar Claire	Chief Executive Officer	Oct 15 '25	Option Exercise	3.79	13,289	50,363	323,181	Oct 15 06:00 PM
Mazumdar Claire	Chief Executive Officer	Oct 13 '25	Option Exercise	3.79	11,445	43,374	321,337	Oct 15 06:00 PM
Mazumdar Claire	Chief Executive Officer	Oct 15 '25	Sale	18.84	13,289	250,391	309,892	Oct 15 06:00 PM
Mazumdar Claire	Chief Executive Officer	Oct 13 '25	Sale	18.92	11,445	216,545	309,892	Oct 15 06:00 PM
Cohlhepp Ryan	Officer	Oct 15 '25	Proposed Sale	18.13	12,500	226,601		Oct 15 04:20 PM
Mazumdar Claire	Officer	Oct 15 '25	Proposed Sale	18.84	13,289	250,391		Oct 15 04:18 PM
Mazumdar Claire	Officer	Oct 13 '25	Proposed Sale	18.92	11,445	216,545		Oct 14 09:05 AM
Raben David	Chief Medical Officer	Oct 09 '25	Option Exercise	3.79	22,000	83,376	57,497	Oct 10 05:23 PM
Raben David	Chief Medical Officer	Oct 09 '25	Sale	18.45	22,000	405,900	35,497	Oct 10 05:23 PM
Hyep Ivan	Chief Financial Officer	Oct 09 '25	Option Exercise	3.79	6,415	24,312	151,770	Oct 10 05:22 PM
Hyep Ivan	Chief Financial Officer	Oct 09 '25	Sale	18.23	6,415	116,931	145,355	Oct 10 05:22 PM
Hyep Ivan	Officer	Oct 09 '25	Proposed Sale	17.89	6,415	114,764		Oct 09 04:31 PM
Raben David	Officer	Oct 09 '25	Proposed Sale	18.45	22,000	405,900		Oct 09 04:08 PM
Hyep Ivan	Chief Financial Officer	Oct 07 '25	Option Exercise	3.79	18,244	69,141	163,599	Oct 08 05:33 PM
Hyep Ivan	Chief Financial Officer	Oct 06 '25	Option Exercise	3.79	6,514	24,687	151,869	Oct 08 05:33 PM
Hyep Ivan	Chief Financial Officer	Oct 08 '25	Option Exercise	3.79	5,627	21,325	150,982	Oct 08 05:33 PM
Hyep Ivan	Chief Financial Officer	Oct 07 '25	Sale	18.22	18,244	332,386	145,355	Oct 08 05:33 PM
Hyep Ivan	Chief Financial Officer	Oct 06 '25	Sale	18.17	6,514	118,356	145,355	Oct 08 05:33 PM
Hyep Ivan	Chief Financial Officer	Oct 08 '25	Sale	18.21	5,627	102,456	145,355	Oct 08 05:33 PM
Cohlhepp Ryan	President and COO	Oct 06 '25	Option Exercise	3.79	24,000	90,955	245,141	Oct 08 05:33 PM
Cohlhepp Ryan	President and COO	Oct 07 '25	Option Exercise	3.79	8,000	30,318	213,541	Oct 08 05:33 PM
Cohlhepp Ryan	President and COO	Oct 06 '25	Sale	18.06	39,600	714,998	205,541	Oct 08 05:33 PM
Cohlhepp Ryan	President and COO	Oct 07 '25	Sale	18.06	10,900	196,844	202,641	Oct 08 05:33 PM
Hyep Ivan	Officer	Oct 08 '25	Proposed Sale	18.17	5,627	102,242		Oct 08 04:04 PM
Hyep Ivan	Officer	Oct 07 '25	Proposed Sale	18.00	18,244	328,392		Oct 07 04:20 PM
Cohlhepp Ryan	Officer	Oct 07 '25	Proposed Sale	18.00	10,900	196,200		Oct 07 04:07 PM
Cohlhepp Ryan	Officer	Oct 06 '25	Proposed Sale	18.06	39,600	714,997		Oct 06 04:36 PM
Hyep Ivan	Officer	Oct 06 '25	Proposed Sale	17.04	6,514	110,998		Oct 06 04:07 PM
Meisner Lara	Chief Legal Officer	Sep 29 '25	Option Exercise	9.24	33,807	312,495	33,807	Oct 01 04:57 PM
Meisner Lara	Chief Legal Officer	Sep 29 '25	Sale	14.75	33,807	498,653	0	Oct 01 04:57 PM
LARA MEISNER	Officer	Sep 29 '25	Proposed Sale	11.71	33,807	395,880		Sep 29 04:38 PM
Meisner Lara	Chief Legal Officer	Sep 15 '25	Option Exercise	5.45	15,829	86,268	15,829	Sep 17 05:01 PM
Meisner Lara	Chief Legal Officer	Sep 15 '25	Sale	11.49	15,829	181,875	0	Sep 17 05:01 PM
Meisner Lara	Chief Legal Officer	Jun 16 '25	Option Exercise	5.45	15,829	86,268	15,829	Jun 18 05:12 PM
Meisner Lara	Chief Legal Officer	Jun 16 '25	Sale	10.43	15,829	165,096	0	Jun 18 05:12 PM
LARA S. MEISNER	Officer	Jun 16 '25	Proposed Sale	10.84	31,658	343,173		Jun 16 04:29 PM
Meisner Lara	Chief Legal Officer	Mar 14 '25	Option Exercise	5.45	79,146	431,346	79,145	Mar 18 06:35 PM
Meisner Lara	Chief Legal Officer	Mar 14 '25	Sale	12.90	79,146	1,021,211	0	Mar 18 06:35 PM
LARA S. MEISNER	Officer	Mar 14 '25	Proposed Sale	13.35	79,146	1,056,599		Mar 14 04:21 PM

Open in Screener

AHCO

AdaptHealth Corp

Nov 25 • 04:00PM ET

9.68

-0.18 -1.83 %

Healthcare • Medical Devices • USA • NASD

Peers: DVA OPCH AMED EHC PNTG CHE MD RDNT ADUS MODV

| Held by: IJR VTI IWM VB VXF CALF IJS SPSM IWN DFAT

Index	RUT	P/E	17.76	EPS (ttm)	0.55	Insider Own	34.23%	Shs Outstand	135.42M	Perf Week	6.37%
Market Cap	1.31B	Forward P/E	9.65	EPS next Y	1.00	Insider Trans	-0.02%	Shs Float	89.07M	Perf Month	2.87%
Enterprise Value	3.14B	PEG	3.17	EPS next Q	0.36	Inst Own	76.50%	Short Float	10.92%	Perf Quarter	5.10%
Income	74.69M	P/S	0.40	EPS this Y	-34.16%	Inst Trans	-1.26%	Short Ratio	9.98	Perf Half Y	6.61%
Sales	3.26B	P/B	0.81	EPS next Y	43.42%	ROA	1.69%	Short Interest	9.73M	Perf YTD	1.68%
Book/sh	11.94	P/C	16.31	EPS next 5Y	5.61%	ROE	4.77%	52W High	11.63 -16.77%	Perf Year	-2.12%
Cash/sh	0.59	P/FCF	6.15	EPS past 3/5Y	-19.58% -	ROIC	2.16%	52W Low	7.11 36.24%	Perf 3Y	-54.40%
Dividend Est.	-	EV/EBITDA	4.74	Sales past 3/5Y	9.93% 43.84%	Gross Margin	18.05%	Volatility	4.96% 4.83%	Perf 5Y	-66.04%
Dividend TTM	-	EV/Sales	0.97	EPS Y/Y TTM	133.76%	Oper. Margin	7.46%	ATR (14)	0.43	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.86	Sales Y/Y TTM	-0.23%	Profit Margin	2.29%	RSI (14)	55.11	Recom	1.62
Dividend Gr. 3/5Y	- -	Current Ratio	1.08	EPS Q/Q	6.72%	SMA20	2.50%	Beta	1.73	Target Price	13.25
Payout	0.00%	Debt/Eq	1.18	Sales Q/Q	1.79%	SMA50	4.90%	Rel Volume	1.82	Prev Close	9.86
Employees	10500	LT Debt/Eq	1.14	Earnings	Nov 04 BMO	SMA200	4.60%	Avg Volume	974.68K	Price	9.68
IPO	May 24, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	-1.66% 2.63%	Trades		Volume	1,769,425	Change	-1.83%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-08-24	Downgrade	Jefferies	Buy → Hold	$14.50 → $8
Nov-08-23	Downgrade	BofA Securities	Neutral → Underperform	$9.50 → $6.50
May-10-23	Downgrade	Stifel	Buy → Hold	$18 → $11
May-10-23	Downgrade	Deutsche Bank	Buy → Hold	$28 → $11.30
May-09-23	Downgrade	BofA Securities	Buy → Neutral	$21 → $12
Sep-27-21	Initiated	SVB Leerink	Outperform	$30
Jul-14-21	Upgrade	Robert W. Baird	Neutral → Outperform	$30 → $36
Apr-13-21	Downgrade	Robert W. Baird	Outperform → Neutral
Mar-18-21	Initiated	Truist	Buy
Jan-26-21	Initiated	BofA Securities	Buy	$46
Dec-10-20	Initiated	UBS	Buy	$49
Aug-10-20	Initiated	Canaccord Genuity	Buy	$31
Jul-01-20	Resumed	SVB Leerink	Outperform	$21
Jun-09-20	Initiated	RBC Capital Mkts	Outperform	$24
Jan-31-20	Initiated	Stifel	Buy	$17
Jan-07-20	Initiated	Jefferies	Buy	$15
Dec-11-19	Initiated	SVB Leerink	Outperform
Dec-10-19	Initiated	Deutsche Bank	Buy

Show Previous Ratings

Nov-17-25 07:59PM	AdaptHealth Corp. Announces Upgraded S&P Global Issue-Level Rating on Senior Unsecured Debt (Business Wire)
Nov-04-25 04:08PM	AdaptHealth Corp (AHCO) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid Strategic ... (GuruFocus.com) +17.38%
09:05AM	AdaptHealth Corp. (AHCO) Misses Q3 Earnings Estimates (Zacks)
07:32AM	AdaptHealth (NASDAQ:AHCO) Beats Q3 Sales Expectations (StockStory)
07:00AM	AdaptHealth Corp. Announces Third Quarter 2025 Results (Business Wire)
07:43AM	Loading…
Nov-03-25 07:43AM	AdaptHealth Corp (AHCO) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Nov-02-25 10:03PM	AdaptHealth (AHCO) Q3 Earnings Report Preview: What To Look For (StockStory)
Oct-30-25 04:05PM	AdaptHealth Corp. to Participate in Upcoming Investor Conference (Business Wire)
Oct-27-25 07:00AM	Halper Sadeh LLC Encourages AdaptHealth Corp. Shareholders to Contact the Firm to Discuss Their Rights (Business Wire)
Oct-13-25 04:05PM	AdaptHealth Corp. Announces Third Quarter 2025 Earnings Release Date and Conference Call (Business Wire)
Oct-03-25 12:01AM	3 Reasons to Sell AHCO and 1 Stock to Buy Instead (StockStory)
Sep-22-25 04:05PM	AdaptHealth Corp. to Participate in Upcoming Investor Conference (Business Wire)
07:22AM	New Strong Sell Stocks for September 22nd (Zacks)
Sep-10-25 11:33PM	Senior Health, Home Health & Hospice Stocks Q2 Highlights: AdaptHealth (NASDAQ:AHCO) (StockStory)
Aug-26-25 08:38AM	Do Options Traders Know Something About AdaptHealth Stock We Don't? (Zacks)
03:45PM	Loading…
Aug-22-25 03:45PM	AdaptHealth, Illumina, Globalstar, Iridium, and Alight Shares Are Soaring, What You Need To Know (StockStory)
Aug-13-25 12:21AM	The 5 Most Interesting Analyst Questions From AdaptHealth's Q2 Earnings Call (StockStory)
12:10AM	AHCO Q2 Deep Dive: Capitated Deal, Segment Turnarounds, and Margin Expansion Shape 2025 (StockStory)
Aug-05-25 03:50PM	Why Are AdaptHealth (AHCO) Shares Soaring Today (StockStory) +10.98%
08:15AM	AdaptHealth Corp. (AHCO) Lags Q2 Earnings and Revenue Estimates (Zacks)
07:49AM	AdaptHealth (NASDAQ:AHCO) Reports Q2 In Line With Expectations But Stock Drops (StockStory)
07:01AM	AdaptHealth Corp. Announces Second Quarter 2025 Results (Business Wire)
07:00AM	AdaptHealth Corp. Partners With a Major National Healthcare System to Become the Exclusive Provider of Home Medical Equipment (Business Wire)
Aug-04-25 04:05PM	AdaptHealth Corp. to Participate in Upcoming Investor Conference (Business Wire)
09:43AM	AdaptHealth Corp (AHCO) Q2 2025 Earnings Report Preview: What to Expect (GuruFocus.com)
Aug-03-25 11:14PM	AdaptHealth (AHCO) To Report Earnings Tomorrow: Here Is What To Expect (StockStory)
Jul-31-25 10:00AM	Insulet (PODD) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Jul-29-25 10:00AM	AdaptHealth Corp. (AHCO) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
12:01AM	3 Reasons AHCO is Risky and 1 Stock to Buy Instead (StockStory)
Jul-16-25 09:39AM	Truist Financial Remains Bullish on AdaptHealth (AHCO) (Insider Monkey)
04:05PM	Loading…
Jul-15-25 04:05PM	AdaptHealth Corp. Announces Second Quarter 2025 Earnings Release Date and Conference Call (Business Wire)
Jul-08-25 05:00PM	Is the Options Market Predicting a Spike in AdaptHealth Stock? (Zacks)
Jun-30-25 04:05PM	AdaptHealth Corp. Closes Transaction to Dispose of Certain Home Infusion Assets and Reduces Debt (Business Wire)
Jun-26-25 06:02PM	5 Revealing Analyst Questions From AdaptHealth's Q1 Earnings Call (StockStory)
May-19-25 08:56AM	AHCO Q1 Earnings Call: Guidance Trimmed as Diabetes and Sleep Segments Face Mixed Recovery (StockStory)
May-13-25 04:01PM	AdaptHealth Corp. to Participate in Upcoming Investor Conferences (Business Wire)
May-07-25 09:00PM	AdaptHealth Corp (AHCO) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic ... (GuruFocus.com) -6.95%
May-06-25 08:15AM	AdaptHealth Corp. (AHCO) Meets Q1 Earnings Estimates (Zacks)
07:00AM	AdaptHealth Corp. Announces First Quarter 2025 Results (Business Wire)
May-05-25 09:51AM	AdaptHealth Corp (AHCO) Q1 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
May-02-25 01:22PM	SYK Stock Falls Despite Q1 Earnings & Sales Beat on Lower '25 EPS View (Zacks)
01:21PM	DexCom Stock Rises Despite Q1 Earnings Miss & Lower Margins (Zacks)
May-01-25 11:46AM	BAX Stock Gains Following Q1 Earnings Beat Estimates, Revenues Up Y/Y (Zacks)
11:34AM	ARAY Stock Down Despite Q3 Earnings Beat Estimates, Revenues Up Y/Y (Zacks)
11:32AM	GKOS Stock Falls Despite Q1 Earnings & Revenue Beat, Margins Decline (Zacks)
10:40AM	CAH Q3 Earnings Beat Estimates, '25 EPS View Raised, Stock Gains (Zacks)
09:13AM	CNMD Stock Up On Q1 Earnings & Sales Beat, Raised 2025 Outlook (Zacks)
Apr-30-25 11:25AM	GE HealthCare Q1 Earnings & Sales Beat Estimates, Net Margin Rises (Zacks)
Apr-29-25 12:00PM	AdaptHealth (AHCO) Upgraded to Buy: Here's What You Should Know (Zacks)
11:40AM	AHCO or SYK: Which Is the Better Value Stock Right Now? (Zacks)
Apr-28-25 09:04AM	1 Healthcare Stock Worth Your Attention and 2 to Turn Down (StockStory)
Apr-25-25 05:09AM	3 Reasons to Avoid AHCO and 1 Stock to Buy Instead (StockStory)
Apr-21-25 04:05PM	AdaptHealth Corp. Announces First Quarter 2025 Earnings Release Date and Conference Call (Business Wire) -5.91%
12:48PM	AdaptHealth, Wix, Pinterest, Monday.com, and The RealReal Shares Plummet, What You Need To Know (StockStory)
Apr-16-25 08:45AM	Abbott (ABT) Q1 Earnings Beat Estimates (Zacks)
Apr-10-25 08:31AM	Boston Scientific (BSX) Surges 6.8%: Is This an Indication of Further Gains? (Zacks) -8.57%
Apr-08-25 08:39AM	Strength Seen in ResMed (RMD): Can Its 3.8% Jump Turn into More Strength? (Zacks) -5.86%
Mar-30-25 10:00AM	Comprehensive Q1 Review Of My Stock Picks + Ratings Updates (Seeking Alpha)
Mar-12-25 05:02AM	Senior Health, Home Health & Hospice Stocks Q4 Teardown: AdaptHealth (NASDAQ:AHCO) Vs The Rest (StockStory) -5.83%
Mar-06-25 04:05PM	AdaptHealth Corp. to Participate in Upcoming Investor Conferences (Business Wire)
Mar-03-25 09:40AM	Is AdaptHealth (AHCO) a Great Value Stock Right Now? (Zacks)
Feb-27-25 10:10AM	AdaptHealth price target raised to $14 from $11 at RBC Capital (TipRanks)
Feb-26-25 08:14AM	Earnings To Watch: The Pennant Group (PNTG) Reports Q4 Results Tomorrow (StockStory)
02:07AM	AdaptHealth Corp (AHCO) Q4 2024 Earnings Call Highlights: Revenue Growth and Strategic ... (GuruFocus.com)
02:02AM	Q4 2024 Adapthealth Corp Earnings Call (Thomson Reuters StreetEvents)
Feb-25-25 01:59PM	Why AdaptHealth (AHCO) Stock Is Trading Up Today (StockStory) +24.44%
08:40AM	AdaptHealth Corp. (AHCO) Q4 Earnings and Revenues Surpass Estimates (Zacks)
07:31AM	AdaptHealth (NASDAQ:AHCO) Posts Better-Than-Expected Sales In Q4, Stock Soars (StockStory)
07:00AM	AdaptHealth Corp. Announces Fourth Quarter and Full-Year 2024 Results and Provides 2025 Outlook (Business Wire)
01:39AM	AdaptHealth Corp (AHCO) Q4 2024 Earnings Report Preview: What to Expect (GuruFocus.com)
Feb-24-25 08:05AM	AdaptHealth Earnings: What To Look For From AHCO (StockStory)
Feb-17-25 09:35AM	Down -16.54% in 4 Weeks, Here's Why AdaptHealth (AHCO) Looks Ripe for a Turnaround (Zacks)
Feb-14-25 04:03AM	Winners And Losers Of Q3: AdaptHealth (NASDAQ:AHCO) Vs The Rest Of The Senior Health, Home Health & Hospice Stocks (StockStory)
04:03AM	Senior Health, Home Health & Hospice Stocks Q3 Results: Benchmarking Brookdale (NYSE:BKD) (StockStory)
04:01AM	Q3 Earnings Highs And Lows: Chemed (NYSE:CHE) Vs The Rest Of The Senior Health, Home Health & Hospice Stocks (StockStory)
Feb-13-25 09:40AM	Should Value Investors Buy AdaptHealth (AHCO) Stock? (Zacks)
Feb-11-25 04:02AM	Q3 Earnings Highlights: Addus HomeCare (NASDAQ:ADUS) Vs The Rest Of The Senior Health, Home Health & Hospice Stocks (StockStory)
Feb-04-25 04:05PM	AdaptHealth Corp. Announces Fourth Quarter and Full Year 2024 Earnings Release Date and Conference Call (Business Wire)
Jan-28-25 09:40AM	Should Value Investors Buy AdaptHealth (AHCO) Stock? (Zacks)
Dec-03-24 08:00AM	AdaptHealth Corp. Announces Appointment of Russell Schuster as Chief Commercial Officer (Business Wire)
Nov-26-24 04:05PM	AdaptHealth Corp. to Participate in the BofA Securities Home Care Conference 2024 (Business Wire)
08:34AM	Implied Volatility Surging for AdaptHealth (AHCO) Stock Options (Zacks)
Nov-12-24 04:05PM	AdaptHealth Corp. to Participate in the Stifel 2024 Healthcare Conference (Business Wire)
Nov-06-24 02:11AM	AdaptHealth Corp (AHCO) Q3 2024 Earnings Call Highlights: Navigating Growth and Challenges (GuruFocus.com) +10.89%
Nov-05-24 06:42PM	Why AdaptHealth Stock Got Thrashed on Tuesday (Motley Fool) -9.56%
08:40AM	AdaptHealth Corp. (AHCO) Surpasses Q3 Earnings Estimates (Zacks)
07:26AM	AdaptHealth Corp. Announces Third Quarter 2024 Results (Business Wire)
Oct-24-24 09:40AM	Are Investors Undervaluing AdaptHealth (AHCO) Right Now? (Zacks)
09:40AM	Are Medical Stocks Lagging AdaptHealth (AHCO) This Year? (Zacks)
Oct-22-24 10:01AM	Do Options Traders Know Something About AdaptHealth (AHCO) Stock We Don't? (Zacks)
Oct-17-24 08:00AM	AdaptHealth Appoints Diana Nole to Board of Directors (Business Wire)
Oct-16-24 08:30AM	AdaptHealth Corp. Announces Third Quarter 2024 Earnings Release Date and Conference Call (Business Wire)
Oct-09-24 05:02PM	AdaptHealth Corp (AHCO) Q2 2024 Earnings Call Highlights: Strategic Growth Amidst Revenue Shifts (GuruFocus.com)
Oct-08-24 09:40AM	Is AdaptHealth (AHCO) Stock Undervalued Right Now? (Zacks)
Sep-17-24 03:28PM	AdaptHealth Stock Earns RS Rating Upgrade (Investor's Business Daily)
Sep-16-24 08:00AM	AdaptHealth Corp. Announces Refinancing of Senior Secured Credit Facility Resulting in Extended Maturity and Reduced Cost of Debt (Business Wire)
Aug-27-24 08:30AM	AdaptHealth Corp. to Participate in the Baird 2024 Global Healthcare Conference (Business Wire)
Aug-26-24 07:30AM	AdaptHealth Corp. Announces New Chief Operating Officer (Business Wire)
Aug-08-24 04:05PM	AdaptHealth Corp. to Participate in the Canaccord Genuity 44th Annual Growth Conference (Business Wire)
Aug-06-24 08:30AM	AdaptHealth Corp. (AHCO) Beats Q2 Earnings and Revenue Estimates (Zacks) -21.06%

AdaptHealth Corp. engages in the provision of home healthcare equipment, supplies and related services. It focuses on sleep therapy equipment to individuals suffering from obstructive sleep apnea (OSA), home medical equipment to patients discharged from acute care and other facilities, oxygen and related chronic therapy services in the home, and HME medical devices and supplies on behalf of chronically ill patients with diabetes care, wound care, urological, ostomy, and nutritional supply needs. The company was founded in 2012 and is headquartered in Conshohocken, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Williams David Solomon III	Director	Aug 22 '25	Sale	9.73	8,200	79,786	50,045	Aug 22 07:33 PM
Rietkerk Shaw	Officer	Dec 19 '24	Proposed Sale	9.70	32,500	315,250		Dec 19 11:02 AM
Clemens Jason A	Chief Financial Officer	Dec 10 '24	Sale	9.35	35,000	327,250	420,719	Dec 12 04:35 PM
JASON A CLEMENS &BIANCA S VITA	Officer	Dec 10 '24	Proposed Sale	9.35	35,000	327,408		Dec 10 04:19 PM

Black Swan Sale

50% Off Elite

NUVL

Nuvalent Inc

LRMR

Larimar Therapeutics Inc

SPRY

ARS Pharmaceuticals Inc

BCAX

Bicara Therapeutics Inc

AHCO

AdaptHealth Corp

Upgrade your FINVIZ experience